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ABSTRACT 
The trophoblast cell layer constitutes the rate-determining barrier for trans-placental 
transfer. Several isoforms of the sulfotransferase enzymes are functional in placenta 
but there is only limited information available on the utility of cultured trophoblast 
cells for studying placental sulfation. We examined the expression and activities of 
four sulfotransferase isoforms (SULT1A1, SULT1A3, SULT1E1, and SULT2A1) in 
primary cytotrophoblast cells and the trophoblast-like BeWo cell line. These isoforms 
have been reported to be functional in human placenta. Our results indicated that the 
phenolic sulfotransferase isoforms, SULT1A1 and SULT1A3, are functional in 
BeWo, as well as in the primary cytotrophoblast cells. SULT2A1 and SULT1E1 are 
not functional in either cell type. We also found that chronic exposure to the 
industrial chemical bisphenol A inhibited SULT1A1 activity. A U-shaped dose-
response curve was observed with inhibition (~30-40%) being observed only at 
intermediate concentrations (10-100 nM). These results suggested that trophoblast 
cells may be used as a suitable in vitro tool to determine the effect of endogenous or 
exogenous substances on placental sulfotransferase activity. Altered metabolic 
activity has the chance of altering fetal exposure to drugs and other substances in the 
maternal circulation. Studies performed in BeWo cells also suggested that one of the 
roles of the placental efflux transporters is the elimination of sulfate metabolites. The 
multidrug resistance-associated proteins (MRPs) played a major role in the 
elimination of 4-nitrophenyl sulfate and acetaminophen sulfate across the basolateral 
(fetal-facing) and apical (maternal-facing) trophoblast membranes respectively. The 
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breast cancer resistance protein (BCRP) played a minor role in the elimination of 
these two sulfate conjugates across the apical membrane. 
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Chapter 1: Introduction 
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1.1 Introduction 
During pregnancy the fetus is often exposed to drugs and foreign chemicals from the 
maternal circulation. For women afflicted with diseases such as diabetes, asthma, 
epilepsy, and psychiatric disorders, taking drugs during pregnancy is often a 
necessity. Approximately 50% of pregnant women take prescription drugs and ~4% 
use drugs that have been found to pose fetal risk in animals and humans [1, 2]. In 
addition, over-the-counter medicines such as non-steroidal anti inflammatory drugs, 
antihistamines, and antacids are also commonly consumed during pregnancy. 
Obvious ethical constraints prevent conducting clinical trials in pregnant women, and 
hence information is lacking on the fetal exposure and safety of many of the drugs 
consumed during pregnancy. Unless the objective is to treat the fetus (e.g. to prevent 
maternal to fetal transmission of HIV), the overall goal of drug delivery during 
pregnancy is reduction of fetal exposure to drugs.  
 
As the placenta forms the physiological barrier between the mother and the fetus 
during pregnancy, determining the placental disposition of a drug helps to ascertain 
the possibility of fetal exposure. Among other placental factors, nutrient transporters, 
efflux transporters, and metabolic enzymes in the placenta are determinants of trans-
placental transfer [3]. The expression and function of placental transporters and 
enzymes change with gestational age and upon exposure to foreign chemicals. Thus, 
it is important to determine the types, functions, and regulation of placental enzymes 
and transporters.    
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1.2 The placental barrier 
Placentation begins 6-8 days post conception when the blastocyst invades the uterine 
endometrium. The blastocyst consists of an outer epithelial cell layer (the trophoblast) 
and an inner cell mass (the embryoblast). Mononuclear proliferative, trophoblast cells 
(cytotrophoblasts) invade the uterine mucosa and fuse together into multinucleated, 
nonproliferative cells (syncytiotrophoblast). They further develop to form “finger-like 
projections” known as villi. Villi that contact and spread around the endometrium are 
known as anchoring villi while villous branches extending into the intervillous space 
are known as free villi. The combination of the anchoring villi and the decidualized 
endometrium is known as the basal plate. Maternal blood enters and leaves the 
intervillous space through the basal plate and in this process the villi are bathed in 
maternal blood. From the chorionic plate (the placental “boundary” on the fetal side) 
mesenchymal cells invade the villi and differentiate to ultimately form the fetal 
capillaries. This arrangement places the trophoblast layer in contact with maternal 
blood on one side and in close apposition to the fetal capillaries on the other side.  
 
During the first trimester the trophoblast layer consists of an outer 
syncytiotrophoblast layer (i.e., a multinucleated layer devoid of any lateral cell 
boundaries) and an underlying cytotrophoblast layer. The latter gradually becomes 
discontinuous with advancing gestation [4-6]. Therefore, the transfer of solutes from 
the maternal to the fetal circulation requires passage through three layers of cells – the 
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syncytiotrophoblast layer, the fetal connective tissue, and the fetal capillary 
endothelium (Figures 1.2.1 and 1.2.2).  
 
 
 
 
 
 
Figure 1.2.1 The mature human placenta showing the villous tree extending 
from the chorionic plate into the intervillous space where they are surrounded in 
maternal blood. The figure also shows the villi vascularized by the fetal blood 
vessels. Abbreviations: BP (basal plate), CP (chorionic plate), IVS (intervillous 
space), and UC (umbilical cord). The figure has been adapted from Kurt Benirschke, 
Peter Kaufmann, Rebecca N. Baergen, Pathology of the human placenta. 2006: 
Springer). 
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Figure 1.2.2 Cross section of the placental villous tree (The figure has been 
adapted from Kurt Benirschke, Peter Kaufmann, Rebecca N. Baergen, Pathology of 
the human placenta. 2006: Springer). 
 
Among these three layers, the syncytiotrophoblast layer constitutes the rate-limiting 
barrier to transfer between the mother and the fetus [4, 6]. The syncytiotrophoblast 
layer is polarized in nature. The maternal-facing plasma membrane which is in direct 
contact with maternal blood is a microvillous membrane, while the fetal-facing 
basement membrane lacks microvilli [4]. In addition to being structurally distinct, the 
two membranes also differ with respect to the transporters expressed on each of them, 
which allows directional transport across the placenta [7]. 
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1.3 Models of the placenta 
1.3.1 In vivo and ex vivo models  
The human placenta is hemochorial in nature, i.e., the chorionic villi invade and 
destroy the uterine decidua in such a way that the trophoblast layer is directly bathed 
in maternal blood [4]. This is in contrast to epitheliochorial placentation  (e.g., pig, 
horse) where the chorionic epithelial cells are in contact with the endometrial 
epithelium, and endotheliochorial placentation (e.g., dog, cat) where the endometrium 
is invaded such that the chorion is in contact with the endothelial cells of the maternal 
capillaries [5]. In vivo studies for determining placental transfer or fetal exposure 
have been conducted in rodents and primates. Both exhibit hemochorial placentation 
[8, 9]. Animal models take into account maternal as well as fetal pharmacokinetics in 
determining drug transfer, but suffer from the disadvantages of anatomical and 
functional placental differences, and different gestational lengths [10].  
 
The ex vivo model of the human placenta most representative of in vivo settings is the 
perfused placental cotyledon. The cotyledon is known as the anatomical unit of the 
placenta and each contains a villous tree. At term, the placenta contains 20-30 
cotyledons. These are isolated from term placenta and retain much of the placental 
structural integrity. The perfused placental cotyledon model has been found to 
reliably predict not only the  mechanism and transfer rates of drugs but in certain 
cases also the extent of fetal transfer [11]. Another ex vivo model is villous tissue 
fragments. Villous fragments retain structural and functional integrity up to at least 3 
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hours in vitro and can be used to assess drug uptake but not drug transfer. The 
advantage of this model over cell culture models is that polarization as well as 
transporter and enzyme expressions are more representative of the in vivo situation 
[12]. 
 
1.3.2 In vitro models 
Cell culture models of the placenta include cytotrophoblast cells isolated from term 
placenta. In primary culture, the cytotrophoblasts do not proliferate but do 
spontaneously differentiate into syncytiotrophoblasts. The cells tend to aggregate in 
the process of differentiation producing large intercellular spaces. This renders 
primary cultures unsuitable for transport studies but they have been used successfully 
to assess drug uptake and metabolism [13]. Another advantage is that they allow the 
study of changes in expression and function of drug transporters and drug 
metabolizing enzymes, as the cells differentiate from cytotrophoblasts into 
syncytiotrophoblasts [14].  
 
Other cell culture models include trophoblast-like cell lines (e.g., BeWo, JAr and 
JEG-3) isolated from malignant choriocarcinomas. The BeWo cell line was derived 
from a methotrexate-resistant tumor. In culture BeWo cells mainly consist of 
moderate-sized, mononuclear, proliferative cells that are morphologically 
cytotrophoblast-like, with a smaller proportion  of larger, multinucleated cells that are 
syncytiotrophoblast-like [15]. Unlike primary cytotrophoblasts, BeWo cells do not 
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spontaneously differentiate into syncytiotrophoblasts in culture but on treatment with 
substances that increase levels of cyclic AMP (e.g., forskolin), they differentiate to 
morphologically represent the syncytiotrophoblasts (i.e., the nuclei cluster, there is no 
plasma membrane in between the nuclei, a dense microvillar brush border appears on 
the apical surface). The morphological differentiation is not accompanied by 
complete biochemical differentiation. Upon forskolin treatment, although human 
chorionic gonadotropin was produced at higher levels, the expression of placental-
alkaline phosphatase and the production of human placental lactogen were not 
significantly different from what was observed in the control cells [16]. Placental 
alkaline phosphatase, human chorionic gonadotropin, and human placental lactogen 
are either expressed or secreted by syncytiotrophoblasts at much higher levels than 
the cytotrophoblasts.  
 
On the other hand, based on efflux transporter expression profile, it has been 
suggested that BeWo is more similar to the syncytiotrophoblast than cytotrophoblasts 
[14]. Grown on transwell inserts the BeWo cells form a polarized, confluent 
monolayer that exhibits asymmetrical transport of several substances including amino 
acids, nutrients, cholesterol, folic acid, and neurotransmitters [17-19]. It also exhibits 
metabolism similar to that of cytotrophoblasts [13]. Other choriocarcinoma cell lines, 
JAr and JEG-3 have been used to study placental uptake but they are unsuited for 
trans-trophoblast studies as they do not form confluent monolayers in culture [12]. 
Most of the work in this thesis has been performed with the BeWo cell line.   
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1.4 Factors affecting placental drug transfer 
As with permeation across any other epithelial or endothelial barrier, drug properties 
influence the extent of placental transfer. As passive diffusion is the major mode of 
placental transfer, smaller molecules (molecular weight < 600 Da), that are lipophilic, 
and exhibit a low degree of ionization, easily cross the placenta [3]. Several maternal, 
placental, as well as fetal factors also affect the fetal/maternal ratio of a drug and this 
section briefly discusses a few factors.  
 
Maternal factors include metabolism, protein binding, and health conditions which 
can influence placental blood flow [3]. For example, pregnancy is associated with 
declining maternal albumin concentrations. This has the potential of increasing the 
fetal exposure of highly protein-bound drugs as a function of gestation [20].  
 
Fetal factors include protein binding, pH and metabolism. Fetal pH is normally 
approximately 0.1 units lower than maternal pH but conditions of fetal acidosis, such 
as is induced during labor, favor the partitioning of basic drugs into the fetal 
compartment [21, 22]. Fetal serum albumin concentrations are ~40% of maternal 
serum albumin concentrations in early pregnancy but steadily rise to exceed maternal 
concentrations near term. Fetal alpha-1 acid glycoprotein concentrations were also 
shown to increase during pregnancy although they never exceeded maternal 
concentrations [23]. The change in fetal/maternal protein concentrations can affect 
the free fraction of the drug in the fetus as a function of gestation. Fetal metabolism is 
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detected as early as 8-9 weeks of gestation [24]. Although the fetal liver does not 
express all the cytochrome P450 (CYP) enzymes detected in the adult liver, several 
CYP isoforms are present. The fetal liver also expresses sulfotransferase and 
glutathione-S-transferase isoforms, and there is evidence of fetal glucuronidation as 
well [9, 25, 26]. 
 
Placental morphology affects the extent of fetal transfer of drugs whose predominant 
mode of transport is passive diffusion since diffusional distance decreases (i.e., the 
syncytiotrophoblast layer decreases in thickness and the newer villi that form are 
smaller) and surface area increases with advancing gestation.  
 
Placental carrier mechanisms include peptide transporters, amino acid transporters, 
serotonin transporter, norepinephrine transporter, organic cationic transporters, etc. 
Structurally similar drugs can compete with the endogenous ligands of these 
transporters to reach the fetus. For example, the antiepileptic drug gabapentin was 
reported to have an umbilical cord/maternal plasma ratio of two indicative of fetal 
accumulation. Placental transfer of gabapentin was proposed to be through the L-type 
amino acid transporter (LAT-1) [27]. Drugs can also restrict nutrient transport to the 
fetus to produce profound pharmacological consequences. For instance, amphetamine 
derivatives inhibit OCTN2-mediated carnitine uptake in placenta [28]. Since the fetus 
cannot synthesize carnitine on it’s own, decreased carnitine transport has the potential 
of causing cardiomyopathy, muscle weakness, and even sudden infant death [28]. In 
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addition to the factors mentioned above, placental efflux and metabolism are also 
determinants of fetal drug exposure. The following section will examine their roles in 
detail.  
 
1.4.1 Placental metabolism 
Placental metabolism is detected as early as the first trimester. CYP1A1 is functional 
throughout pregnancy [13, 29]. CYP2E1 protein is detected as early as the first 
trimester but is not functionally active [30]. In term placenta, CYP2E1’s protein was 
detected only in alcoholic patients suggestive of alcohol inducibility, although this 
exhibited inter-individual variation [31]. Transcripts of several other CYP isoforms 
have been detected. Some of these are expressed throughout pregnancy but no data is 
available on their functional activity (e.g., CYP1B1, CYP2F1); others are detected 
only in the first trimester but not at term (e.g., CYP1A2, CYP3A7) [22, 29, 32]. 
CYP3A4 which is quantitatively the most abundant CYP in the liver does not display 
any placental activity [33]. Two steroid-metabolizing isoforms, CYP11A1 (associated 
with cholesterol side-chain cleavage activity which is the first rate-limiting step in 
steroid hormone production) and CYP19 (which catalyzes the conversion of 
androstenedione to estrogens), are constitutively expressed [34]. Selected isoforms of 
the phase II enzymes, N-acetyltransferase (NAT), glutathione-S-transferase (GST), 
uridine-diphosphate-glucuronosyl-transferase (UGT), and sulfotransferase (SULT) 
enzymes are functional in the placenta with UGT activity being greater in the first 
trimester than at term [30]. The overall pattern of expression and function seems to 
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indicate that placental metabolism has a more important role during the early stages 
of pregnancy when fetal metabolism has not developed completely. Further, the lack 
of functional activity of many placental enzymes has led to the theory that while 
placental metabolism may influence fetal accumulation of a particular drug, it may be 
of greater significance from a toxicological view point since placental enzymes have 
been found to produce mutagenic or toxic metabolites that pose fetal risk.    
 
Exposure to foreign chemicals (e.g., maternal drugs, components of cigarette smoke) 
can change placental metabolic activity. Smoking induces CYP1A1 and UGT 
activity, while the anti-HIV drug Azidothymidine induces CYP1A1 and GST, but 
decreases UGT activity [13, 30, 35]. In a comparative study, it was observed in the 
placenta of smokers, that CYP1A1 activity and CYP1B1 mRNA were significantly 
induced, CYP19A1 (aromatase) activity was reduced, while there was no alteration in 
the genetic expression of phase II enzymes [36]. As CYP1A1, CYP1B1, and 
CYP19A1 are contributors in the placental estrogen synthesis pathway, it was 
suggested that smoking may adversely affect this pathway. Cadmium, a component of 
cigarette smoke, decreases 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) 
activity in trophoblast, at concentrations similar to its concentrations detected in 
placenta. It was proposed that in vivo this has the chance of producing fetal growth 
restriction [37].  
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1.4.1.1 Placental sulfation 
Sulfation involves the transfer of a sulfate group from a donor molecule 3’-
phosphoadenosine-5’-phosphosulfate (PAPS) to acceptor molecules containing 
amine, hydroxyl, N-hydroxyl, or sulfhydryl groups. The reaction is mediated by 
sulfotransferase (SULT) enzymes which may be either cytosolic or membrane-bound. 
The cytosolic enzymes sulfate small molecules that include endogenous substances 
(e.g., estradiol, thyroid hormones, bile acids, and neurotransmitters), several drugs 
and environmental chemicals. Sulfation is mostly a detoxification pathway but in 
certain cases substrates (e.g., benzylic alcohols derived from polycyclic aromatic 
hydrocarbons, N-hydroxylated derivatives of homocyclic and heterocyclic amines, 
nitroalkanes etc.) are activated to produce carcinogenic DNA adducts [38].  
 
The sulfation of several drugs has been detected and several sulfotransferase isoforms 
have been identified in the placenta [39]. Examination of sections of whole placental 
tissue revealed that the phenolic sulfotransferase isoforms SULT1A1 and SULT1A3 
were functional in all sections of placental tissue of both maternal and fetal origin. 
Highest activity was reported in sections containing syncytiotrophoblasts [40]. 
SULT1E1 (estrogen sulfotransferase) protein expression was reported to be low in 
fractions rich in syncytiotrophoblasts. Other studies have reported abundant estrogen 
sulfotransferase in the placenta and have localized the protein to the 
syncytiotrophoblast [41, 42]. Placental dehydroepiandrosterone sulfation was 
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attributed to SULT2A1 activity [40]. Another isoform, SULT2b1b, which sulfates 
cholesterol with a high affinity, is localized to the nuclei of syncytiotrophoblast [43].  
 
Among the 13 human cytosolic sulfotransferase genes identified thus far, SULT1A1 
is the major sulfotransferase in the human liver. It is also functional in the 
gastrointestinal tract (GIT) and platelets. SULT1A1 sulfates a wide range of 
substrates that includes among others estradiol and thyroid hormones[44]. Genetic 
polymorphisms in SULT1A1 which lead to lower enzyme activity have been 
associated with upper aerodigestive tract multiple primary neoplasms (UADT-MPN), 
upper urinary tract urothelial cell carcinoma (UUT-UUC), meningiomal brain tumors, 
and squamous cell carcinoma of the head and neck (SCCHN) [45-48]. Endogenous 
substrates of SULT1A3 include neurotransmitters and the enzyme is functional in the 
gastrointestinal tract and the brain. SULT1E1 sulfates 17β-estradiol with the highest 
affinity compared to any of the other sulfotransferase isoforms and is functional in the 
liver, GIT, and the endometrium [49]. SULT2A1 is predominantly functional in the 
adrenal gland and sulfates steroid hormones (DHEA), cholesterol, and bile acids [44]. 
SULT2A1, SULT1E1, and SULT1A3 are also well developed in fetal tissues [44]. 
Although, SULT1A1, SULT1A3, SULT1E1, and SULT2A1 have been extensively 
characterized in other human tissue, there has not been much work regarding their 
trophoblast localization. Hence, a part of the objective of this research project was to 
determine the functional activities of the four sulfotransferase enzymes mentioned 
above in the BeWo cells and primary cytotrophoblast cells.  
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1.4.2 Placental efflux transport 
The placenta expresses several efflux transporters on both syncytiotrophoblast  
membranes and the fetal capillary endothelium. Efflux transporters located on the 
brush border membrane include P-glycoprotein (P-gp/MDR1/ABCB1), the breast 
cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated 
protein (MRP/ABCC) isoforms 1-5 [12]. Efflux transporters located on the 
basolateral membrane include MRP1 and MRP5 [50, 51]. One of the supposed 
functions of the efflux transporters located on the apical membrane is the reduction of 
fetal exposure to drugs and foreign chemicals. Control of fetal exposure to 
xenobiotics is suggested by several examples. When a fraction of the CF-1 mice 
naturally lacking the mdr1a gene that leads to a loss of placental P-gp were exposed 
to avermectin during pregnancy, it was observed that fetuses with the genotype 
Mdr1a(-/-) were most susceptible to avermectin-induced cleft palate [52]. Similarly, 
there was a 3.2 fold greater fetal accumulation of the BCRP substrate topotecan in 
Mdr1a/1b(-/-) knockout mice treated with a dual P-gp and BCRP inhibitor, compared 
to mice where the inhibitor was not used [8]. In the human perfused placental model, 
P-gp limited the maternal to fetal transfer of the HIV protease inhibitor indinavir 
while BCRP limited the maternal-to-fetal clearance of the antidiabetic glyburide [53, 
54]. On the other hand efflux transporters on the basolateral membrane are likely to 
increase fetal exposure to substances. Interestingly, it has been observed that the 
expression and activity of the efflux transporters change with gestational age. With 
increasing gestational age, P-gp function decreases and MRP2 function increases [51, 
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55, 56]. Many of the studies assessing the trans-placental transfer of drugs are 
performed in ex vivo models of the human placenta. The results of these studies often 
report the extent to which a particular transporter influences fetal accumulation and 
therefore may not be very reflective of the earlier stages of pregnancy [53, 54].  
 
Genetic polymorphisms in transporters have been postulated to be a reason for the 
inter-individual differences observed in drug response. Single nucleotide 
polymorphisms in BCRP and P-glycoprotein have been found to lead to low placental 
expression but not much work has focused on the effects of polymorphism on trans-
placental transfer. Using an ex vivo placental model it was observed that one such P-
glycoprotein polymorphism that led to low protein expression did not affect the 
transfer of the P-gp substrate saquinavir [57].  
 
1.4.2.1 Placental sulfate conjugate efflux 
While P-gp substrates are neutral or cationic, BCRP and MRP substrates also include 
anionic compounds. This suggests another role of BCRP and the MRP isoforms i.e., 
the removal of anionic conjugates. BCRP effluxes sulfate and glucuronide conjugates, 
while the MRP isoforms eliminate sulfate, glucuronide, as well as glutathione 
conjugates. This role of the efflux transporters has been seen in the liver, intestine, 
and kidney [58-64].  
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Species as well as tissue differences exist with respect to the relative contribution of 
the efflux transporters in sulfate elimination. For e.g. while in mice BCRP mediated 
the biliary elimination of acetaminophen sulfate with a minor contribution from 
MRP2, it was the opposite in rats [60, 61]. In mice, ~30% of the biliary efflux of 
troglitazone sulfate was via BCRP but BCRP played only a limited role in preventing 
the oral absorption of troglitazone sulfate [62].  
 
Although it has been proposed that one of the roles of the MRP isoforms and BCRP 
in the placenta is the elimination of conjugates, this has not yet been investigated. 
However, altered sulfate transport has been associated with profound toxicological 
consequences in other tissues. For example, the antidiabetic drug troglitazone was 
withdrawn from the market due to drug-induced liver toxicity. Troglitazone and 
troglitazone sulfate inhibit the hepatic bile salt export pump (BSEP) to cause 
increased hepatic accumulation and hence increased serum levels of bile acids [65]. 
Troglitazone sulfate is a more potent BSEP inhibitor [65]. MRP2 eliminates 
troglitazone sulfate. Serum levels of bilirubin were higher in MRP2-deficient rats 
compared to wild type rats [65]. Thus not only is troglitazone sulfate toxic but its 
impaired hepatic excretion exacerbates this toxicity. The examples of troglitazone 
sulfate, as well as the differential involvement of the efflux transporters in sulfate 
conjugate elimination, underscore the importance of determining the transporters 
responsible for sulfate elimination in placental tissue. 
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1.5 Specific objectives 
The objectives of this thesis research were to identify the sulfotransferase enzymes 
functional in trophoblast, determine the induction/inhibition of sulfotransferase 
enzymes in trophoblast, and elucidate the mechanisms of sulfate elimination from 
trophoblast cells.  
 
In chapter 2 we assessed the mRNA expression and enzyme activities of selected 
sulfotransferase isoforms (SULT1A1, SULT1A3, SULT1E1, and SULT2A1) in 
BeWo cells and primary cytotrophoblast cells. Substrates used for determining 
SULT1A1, SULT1A3, SULT1E1, and SULT2A1 activities were 4-nitrophenol, 
dopamine, 17β-estradiol, and dehydroepiandrosterone respectively.  
 
In chapter 2 SULT1A1 was determined to be one of the enzymes functional in BeWo 
cells. There is much evidence in the literature that indicates that SULT1A1 is 
inhibited by estrogenic substances on acute exposure. Bisphenol A, exhibits 
estrogenic properties in vitro. It also achieves moderate placental concentrations. In 
chapter 3 the effects of chronic exposure to bisphenol A on SULT1A1 activity are 
discussed. It was also examined whether the inhibitory effect was mediated through 
the nuclear estrogen receptor (ER) β. 
 
In chapter 4 the efflux transporters mediating the elimination of sulfate metabolites 
from the apical and basolateral trophoblast membranes were determined. BeWo cells 
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were used as a trophoblast model. Among the efflux transporters that eliminate 
sulfate metabolites in other tissues, BCRP, MRP1, MRP2, and MRP5 are expressed 
in BeWo cells. In syncytiotrophoblasts, BCRP and MRP2 are localized to the 
maternal-facing membrane, while MRP1 and MRP5 are localized to both membranes. 
Compared to MRP1 or MRP2, BCRP mRNA is upregulated in BeWo cells. This led 
to the initial hypothesis that BCRP would be responsible for sulfate elimination from 
the apical (maternal-facing) trophoblast membrane.   
 
Chapter 5 is a summary of the findings and conclusions drawn from each part of the 
research work. It also lists the future directions.  
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Chapter 2: Expression and Functional Activities of Selected Sulfotransferase 
Isoforms in BeWo Cells and Primary Cytotrophoblast Cells 
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2.1 Introduction 
Metabolism is one of the many potential factors that modify trans-placental drug 
transfer [1, 2]. Several phase I and phase II metabolic enzymes are active in placenta. 
This includes the sulfotransferase enzymes. Sulfotransferase (SULT) enzymes 
catalyze the transfer of a sulfuryl group (SO3
-1
) from a physiological donor substrate 
3’-phosphoadenosine-5’-phosphosulfate (PAPS) to acceptor substrates containing 
hydroxyl, amine, N-hydroxyl, or sulfhydryl groups in a process known as sulfation. 
They can be either cytosolic or membrane-associated. Membrane-bound 
sulfotransferase enzymes sulfate large biomolecules such as carbohydrates and 
proteins that are involved in extracellular signaling events. The cytosolic enzymes 
sulfate small molecules that include steroid hormones, neurotransmitters, and bile 
acids. Sulfoconjugates are generally inactive but certain sulfated metabolites are 
pharmacologically active (e.g., minoxidil, morphine). There are also examples of 
sulfated conjugates being potentially carcinogenic. Many SULT substrates are 
substrates of the Uridine Diphosphate-Glucuronosyltransferase (UGT) enzymes as 
well. However, sulfation is a high affinity and low capacity reaction in contrast to 
glucuronidation which is a high capacity, low affinity reaction.  
 
In human tissues, 13 cytosolic SULT isoforms have been identified so far out of 
which four isoforms have been very well characterized. These are SULT1A1, 
SULT1A3, SULT1E1, and SULT2A1. In earlier studies SULT1A1 and SULT1A3 
(also known as phenolic sulfotransferases) were referred to as TS-PST/P-PST and 
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TL-PST/M-PST. The nomenclature was based on their differential thermal stability 
and substrate specificity, SULT1A1 being referred to as the thermostable phenol-
specific phenol sulfotransferase and SULT1A3 as the thermolabile monoamine-
specific phenol sulfotransferase. The tissue distributions as well as some of the 
substrates of these four sulfotransferase isoforms have been listed in table 2.1. 
Although there is overlapping substrate recognition there is some degree of substrate 
specificity. For example, 17β-estradiol is sulfated by SULT1A1, SULT1E1, and 
SULT2A1, but only SULT1E1 mediates sulfation at nanomolar concentrations [3]. 
High affinity substrates of SULT1A1 include small, planar phenolic compounds 
while SULT1A3 sulfates monoamines with a high affinity. Endogenous substrates of 
SULT1A1 include 17β-estradiol and thyroid hormones (T3 and T4).  Endogenous 
substrates of SULT1A3 include catecholamines (dopamine, epinephrine, and 
norepinephrine). Both SULT1A1 and SULT1A3 also sulfate medicinal drugs. The 
wide range of substrates accepted by each isoform makes it difficult to assign a 
particular physiological function but does suggest a major role in xenobiotic 
elimination.  
 
SULT1E1 (also previously known as estrogen sulfotransferase), exhibits the highest 
affinity for estrogens among all the sulfotransferase enzymes [4]. As it sulfates 17β-
estradiol at physiological concentrations, SULT1E1’s physiological functions are 
most likely concerned with maintaining estrogen balance, and protection of tissues 
from the untoward effects of estrogen [5, 6].  
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SULT2A1 sulfates hydroxysteroids such as dehydroepiandrosterone (DHEA). In the 
liver, SULT2A1 is responsible for majority of the bile acid sulfation [4, 7]. Sulfated 
DHEA serves as the source of estrogens and androgens in peripheral tissues.  
 
All four isoforms are functional in the liver, with SULT1A1 activity being much 
higher than that of the others [8]. In contrast to SULT1A1, whose hepatic activity is 
greater than its intestinal activity, SULT1A3 is predominantly expressed in the 
intestine with very low hepatic activity [8, 9]. Hepatic SULT1E1 activity has been 
reported to be similar or greater than small intestinal activity, while SULT2A1 
activity is higher in the liver [8, 10]. All four isoforms are expressed in other tissues 
(table 2.1) but there is lack of information on their relative levels of expression. 
Thermostable phenol sulfotransferase (SULT1A1) has been reported to be functional 
in bovine brain microvessel endothelial cells [11]. The presence of sulfotransferase 
isoforms in the liver, intestine, and blood brain barrier indicates a protective role of 
the enzymes against xenobiotic exposure.  
 
SULT1A1 and SULT1A3 mRNA levels in the placenta were reported to be much 
higher than that of SULT1E1, while SULT2A1 was not detected [12]. SULT1A1 and 
SULT1A3 activities have been detected in term and mid-gestation human placenta 
[13, 14]. Examination of enzyme activities in placental fractions of maternal as well 
as fetal origin revealed SULT1A1 and SULT1A3 to be functional in all fractions. 
Enzyme activities and expression were highest in placental sections that  
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Table 2.1 Tissue distributions and typical substrates of SULT1A1, SULT1A3, 
SULT1E1, and SULT2A1 
 
SULT 
isoform 
Substrate  Major sites of expression 
SULT1A1 
 
 
 
Endogenous 
17β-estradiol, 3,3’-T2, dopamine, 
epinephrine 
Exogenous  
4-nitrophenol, 2-naphthol, paracetamol, 
minoxidil, troglitazone, epicatechin, 
apomorphine, cis- and trans- 4-
hydroxytamoxifen, genistein, daidzein 
Liver, platelets, brain, 
gastrointestinal tract, 
placenta, lung, kidney. 
 
SULT1A3 
 
Endogenous 
Dopamine, norepinephrine, 2-hydroxy-
estradiol 
Exogenous  
p-nitrocatechol, m-nitrocatechol, 4-
nitrophenol, epicatechin, albuterol, 
apomorphine,ethinyl estradiol, 
minoxidil, troglitazone 
Gastrointestinal tract, 
platelets, brain, placenta, 
lung, kidney. 
SULT1E1 Endogenous 
17β-estradiol, estrone, pregnenolone, 
DHEA 
Exogenous 
17α-ethinylestradiol, 3α- 
hydroxytibolone, 3β-hydroxytibolone, 
apomorphine, cis-4-hydroxytamoxifen, 
trans-4-hydroxytamoxifen, minoxidil, 
troglitazone, naringenin, genistein 
Endometrium, mammary 
epithelium, liver, 
gastrointestinal tract. 
SULT2A1 Endogenous 
DHEA, testosterone, 17β-estradiol, 
cholesterol, lithocholic acid 
Exogenous 
17-ethinyl-estradiol, 3β-
hydroxytibolone, budesonide, 
minoxidil 
 
Adrenal gland, brain, liver, 
gastrointestinal tract. 
 
Information summarized from Lindsay et al. [15], Chapman et al. [3], Pacifici et al. 
[16], Baranczyk-Kuzma et al. [11]. 
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predominantly consisted of syncytiotrophoblasts [14]. Similarly SULT2A1 activity 
was reported to be highest in sections that predominantly consisted of 
syncytiotrophoblast cells [14]. SULT1E1 has also been localized to the 
syncytiotrophoblasts [17]. The enzyme activities did not vary as a function of 
gestational age [14]. There is only limited information available on whether cultured 
trophoblast cells may serve as suitable in vitro models for studying placental 
sulfation. Tamura et al. have detected mRNA of several sulfotransferase isoforms in 
BeWo [18]. Since the trophoblast layer consisting of multinucleated 
syncytiotrophoblast cells and mononucleated cytotrophoblast cells is the rate-limiting 
barrier in the placental transfer of substances, the BeWo cell-line which is a 
trophoblast-derived cell line is often used to model the human placenta. In some cases 
it has been shown to be adequately representative of placental metabolism [19].  The 
objective of this work was to determine the expression and activities of SULT1A1, 
SULT1A3, SULT1E1, and SULT2A1 in primary cytotrophoblast cells and in the 
BeWo cell line.  
 
2.2 Materials and methods 
2.2.1 Cell culture 
The BeWo cell line (clone b30) was obtained from Dr. Alan Schwartz (Washington 
University, St. Louis, MO) and cultured as described previously[20]. Passages 29 
through 45 of the cells were used in this study. Briefly, cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, St. Louis, MO) containing 
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10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA) and 1% 
each of 10,000 U/ml penicillin with 10,000µg/mL streptomycin solution, 200mM L-
glutamine solution, and 10mM minimal essential medium nonessential amino acid 
solution (all three were from Invitrogen, Carlsbad, CA). Cells were maintained at 
37°C under 5% CO2 and 95% relative humidity. The medium was changed every 
other day. At 70-90% confluence, cells were detached with 0.5% trypsin and 0.2% 
ethylenediaminetetraacetic acid (EDTA, Sigma, St. Louis, MO) solution diluted in 
phosphate buffered saline (PBS) at a 1:10 ratio. Cells were subcultured at a ratio of 
1:10. Cytotrophoblast cells were obtained from Dr. Joan S. Hunt (University of 
Kansas Medical Center, Kansas City, KS). They were isolated from placenta 
following an uncomplicated caesarean delivery as per the procedure of Petroff et al. 
[21] and stored under liquid nitrogen until further use.  
 
2.2.2 Homogenate preparation for sulfotransferase assays 
BeWo cell homogenate was prepared as described previously with some 
modifications [22]. Cells at confluence were washed and scraped in PBS containing 
0.5 mM EDTA (Sigma, St. Louis, MO) and 1mM phenylmethylsulfonylfluoride 
(PMSF, Sigma, St. Louis, MO). Cells were then centrifuged, PBS was aspirated off, 
and the cells were homogenized in 5 mM potassium phosphate buffer (pH 7.4) 
containing 1.25 mM EDTA, 2.5 mM dithiothreitol (DTT), and Complete Mini 
Protease Inhibitor cocktail tablets (Roche, Indianapolis, IN) at 4ºC for 20 strokes 
using a Dounce homogenizer. Homogenates were centrifuged at 13,000 x g for 20 
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minutes at 4ºC. The supernatant was further centrifuged at 100,000 x g for 1 hour at 
4ºC. The resulting high speed supernatant was used for protein determination. It was 
then diluted 1:1 in a BSA solution (5 mM potassium phosphate buffer, pH 7.4, 
containing 5 mg/mL BSA) and stored at -70ºC. Cytotrophoblast homogenate was 
prepared in a similar manner.  
 
2.2.3 Western blot analysis 
BeWo cells at confluence were rinsed thrice in PBS and scraped off. The cell 
suspension was centrifuged at 1,500 rpm for 8 minutes. The pellet was then 
resuspended in lysis buffer containing 20 mM Tris HCl, 150 mM NaCl, 1 mM PMSF, 
1% (v/v) Triton X-100 (all from Sigma, St. Louis, MO), and Complete Mini Protease 
Inhibitor cocktail tablets (Roche, Indianapolis, IN). This was maintained on ice for 30 
minutes. The cell lysate was then centrifuged at 14,000 rpm for 10 minutes at 4ºC. 
Protein concentration of the supernatant was determined with the BCA assay (Pierce, 
Rockford, IL) and the supernatant was stored at -80ºC until further analysis. Before 
electrophoresis, 20-80 µg cytosolic protein was added to loading buffer and loaded 
onto a 12% Tris-glycine gel (Invitrogen, Carlsbad, CA). Sample pretreatment 
included testing the effects of boiling and the inclusion of DTT in the samples. Sf-9 
insect cell cytosolic extract from insect cells transfected with human SULT2A1 
cDNA (Panvera, Carlsbad, CA) served as the positive control. Electrophoresis was 
performed at 110 V for 2 hours. Protein bands were transferred at 25 V for 4 hours 
onto a nitrocellulose membrane (Invitrogen, Carlsbad, CA). The membrane was 
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blocked overnight with 5% (w/v) nonfat milk in TBS buffer (10 mM Tris buffer, pH 
8.0, 150 mM NaCl, both from Sigma, St. Louis, MO) at room temperature, washed, 
and then incubated with a commercially available polyclonal antibody (Panvera, 
Carlsbad, CA) to SULT2A1 at a 1:500 dilution for 1 hour at room temperature. After 
incubation the membrane was washed 6 times at 10 minute intervals in 1.5% BSA in 
TBST buffer (TBS buffer containing 0.1% v/v Tween 20). The membrane was then 
incubated in secondary antibody (peroxidase-conjugated AffiniPure goat antirabbit 
IgG, Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 hour. The 
membrane was washed 6 times at 10 minute intervals in TBST buffer and the protein 
was visualized by chemiluminescence. The Enhanced Chemiluminescence Western 
blotting detection reagents were obtained from Amersham Biosciences (Little 
Chalfont, Buckinghamshire, UK).  
 
2.2.4 Determination of sulfotransferase enzyme activities 
Sulfotransferase enzyme assays were performed with the appropriate diagnostic 
substrates: 4-nitrophenol (Sigma, St. Louis, MO) for SULT1A1, dopamine (Sigma, 
St. Louis, MO) for SULT1A3, dehydroepiandrosterone (DHEA, (Sigma, St. Louis, 
MO)) for SULT2A1, and 17β-estradiol (Sigma, St. Louis, MO) for SULT1E1.  
 
Enzyme assays for SULT1A1 and SULT1A3 were a modification of the method of 
Foldes and Meeks [23]. The complete reaction mixture consisted of 0.4 µM [
35
S]-3’-
phosphoadenosine-5’-phosphosulfate (PAPS, Perkin El
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concentrations of the acceptor substrates, and BeWo/primary cytotrophoblast protein 
(20 µg) in 20 mM potassium phosphate buffer (pH 7.4). The final reaction volume 
was 150 µL. Control reactions did not contain the acceptor substrate. Reactions were 
started by the addition of PAPS to the other components and incubated at 37
o
C for 20 
minutes. The reaction was terminated by adding 0.1 M barium hydroxide, 0.1 M 
barium acetate, and 0.1 M zinc sulfate to precipitate the enzyme and the unreacted 
[
35
S] PAPS. The sulfated product was determined by liquid scintillation counting. 
Each assay was performed at least in duplicate.  
 
17β-estradiol (E2) sulfation was measured using a method based on that of Harris et 
al. [24]. The reaction mixture consisted of 10 µM PAPS, BeWo cytosolic protein (50 
µg) in a final volume of 200 µL in 100mM Tris buffer containing 10mM magnesium 
acetate and 0.1 mM EDTA (pH 7.9). Reactions were started by the addition of 
[2,4,6,7-
3
H(N)]-estradiol (0.5 Ci/mmol, Perkin Elmer, Waltham, MA) and incubated 
at 37
o
C for 40 min. Reactions were terminated by the sequential addition of ice cold 
deionized water (200µL) and ice cold dichloromethane (800µL). The tubes were 
mixed vigorously for 30 sec, the phases were separated by centrifugation at 11,500 x 
g for 5 min, and radioactivity was determined in the aqueous phase that contained 
sulfated estradiol. 
 
DHEA (Perkin Elmer, Waltham, MA) sulfation was measured using the protocol 
published by Chen et al. [8]. The reaction mixture consisted of 20 µM PAPS, BeWo 
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cytosolic protein (50-600 µg), 3 µM or 10 µM DHEA (diluted to 0.4 Ci/mmol) in 50 
mM Tris buffer (pH 6.2) in a final volume of 250 µL. After incubation at 37
o
C for 30 
minutes, the reaction was stopped by the addition of 250 µL of 0.25 M Tris buffer 
(pH 8.7) and 1 mL chloroform. The extraction was repeated twice and an aliquot of 
the aqueous phase was used for scintillation counting.  
 
2.2.5 Reverse transcription polymerase chain reaction (RT-PCR)  
BeWo cells at confluence were washed, scraped in PBS, and then centrifuged to 
remove the PBS. Cytotrophoblast cells were retrieved from liquid nitrogen, thawed, 
and centrifuged to remove storage medium. Total RNA was isolated from either 
BeWo cells or cytotrophoblast using a commercially available phenol-guanidine 
isothiocyanate solution (TRIZOL reagent, Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol. mRNA was purified from total RNA using an Oligotex 
mRNA Mini Kit (Qiagen, Valencia, CA) as per the manufacturer’s protocol and 
stored at -80ºC until further use. The mRNA was concentrated prior to the experiment 
by mixing volume enough to give 200 ng with 1/10
th
 the volume of 3M DEPC treated 
sodium acetate (pH 5.2),  2 µL glycogen (Roche Diagnostics, Indianapolis, IN), and 
ethanol (at a volume 2.5 fold more than the volume of mRNA). This was stored 
overnight at -20ºC to precipitate the mRNA. After overnight precipitation, the sample 
was spun down at 14,000 rpm for 15 minutes at 4ºC. The supernatant was aspirated 
off, the pellet was washed in 75% ethanol, and the tubes spun down at 14,000 rpm for 
15 minutes at 4ºC. Most of the supernatant was aspirated off. The remainder was 
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dried in room air and reconstituted in RNAse free water prior to reverse transcription. 
200 ng mRNA was reverse transcribed and amplified using the Access RT-PCR 
Introductory System (Promega, Madison, WI). The primer sequences for amplifying 
SULT1A1, SULT1A3, SULT2A1 and SULT1E1 have previously been published  
[18, 25, 26] and have been listed in table 2.2. Specific primers were not designed for 
SULT1A2. Instead, primers were used that can simultaneously amplify SULT1A1, 
SULT1A2, and SULT1A3 cDNAs [25]. This will henceforth be referred to as 
SULT1A cDNA. All primers were synthesized by the Biotechnology Support Facility 
at the University of Kansas Medical Center (Kansas City, KS). The primers utilized 
for amplifying β-actin transcripts were obtained from Promega (Madison, WI). PCR 
cycle parameters were according to manufacturer’s protocol and were as follows: 1 
cycle each of reverse transcription at 48
o
C for 45 minutes and denaturation for 2 min 
at 94°C, followed by 40 cycles each of denaturation at 94
o
C for 30 seconds, annealing 
at 60
o
C for 1 minute, and extension at 68
o
C for 2 minutes. This preceded a final 
elongation at 68°C for 7 minutes.  
 
SULT1A and SULT1A1 cDNA were further subjected to restriction digest analysis 
(Sty I and Hind III, Promega, Madison, WI) [25]. The RT-PCR product was purified 
with the Wizard
®
 DNA Clean-up System (Promega, Madison, WI) and each 
restriction digest was set up with 200 ng mRNA for 1 hour as per the manufacturer’s 
protocol. 
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Electrophoresis of all RT-PCR products was performed at 80 V on a 2% agarose gel. 
The gel was post-stained with 0.5 µg/mL ethidium bromide for 45 minutes, washed 
four times in distilled water at 10 minute intervals, and viewed with a UV 
transilluminator.  
 
2.2.6 RT-PCR product sequencing  
For sequencing SULT1A1 cDNA, a small portion of the gel below the desired band 
was cut off and replaced with 1% low-melt agarose. Electrophoresis was resumed 
until the band migrated into this area. This portion of the gel was then removed and 
purified with the Wizard
®
 DNA Clean-up System (Promega, Madison, WI). The 
purified PCR product was then inserted into a pCR®II-TOPO® plasmid vector using 
a TOPO TA Cloning kit (Invitrogen, Carlsbad, CA). The vector was transformed into 
One Shot® TOP10F’ chemically competent E. Coli cells. Colonies were selected 
from LB plates and broth (Becton Dickinson, Sparks, MD) containing 50 µg/mL 
kanamycin. Plasmid DNA was isolated and purified with the Wizard® Plus SV 
Minipreps DNA Purification System (Promega, Madison, WI). Plasmid DNA was 
then subjected to restriction digest (Hind III and Sty I) to verify the orientation of the 
cloned PCR product. The products were sequenced at the University of Kansas 
Medical Center Biotechnology Support Facility (Kansas City, KS). cDNA 
purification, cloning, transformation, and plasmid DNA purification were all 
performed according to manufacturers’ protocols.  
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Table 2.2 Primer sequences used for reverse transcribing sulfotransferase mRNA and 
expected base pair sizes of the reaction products 
 
Target 
sequence 
 
Genbank 
accession 
ID 
 
Primers 
(Forward, Reverse) 
Expected size 
(Expected size 
after digest) 
SULT1A1 
(39-1025) 
L10819 5’-ATGGAGCTGATCCAGGACAC-3’ 
5’-TGACCTACCGTCCCAGGCCC-3’  
987 
(Sty I : 437,550) 
SULT1A1 
(42-808) 
SULT1A2 
(74-840) 
SULT1A3 
(22-788) 
L19955 
 
U28169 
 
X84653 
5’-ATGGAGCTGATCCAGGACAC-3’  
5’-ATGAAGGGGGAGATGCTGT-3’ 
767 
(Sty I : 437,330) 
767 
(HindIII: 
468,299) 
767 
(Sty I : 656,111) 
SULT1A3 
(139-1125) 
L19956 5’-ATGGAGCTGATCCAGGACAC-3’  
5’-TGAGCCACTGTGCCTGACTC-3’  
987 
 
SULT1E1 
(389-852) 
Y11195 5’-ACCTGAACTTCTTCCTGCC-3’  
5’-TCCAGTCTCCTGTAATTCCC-3’ 
464 
SULT2A1 
(21-875) 
U08024 5’-ATGTCGGACGATTTCTTATG-3’  
5’-AATCCCATGGGAACAGCTC-3’  
856 
 
2.2.7 Data analysis 
SULT1A1 and SULT1A3 enzyme activity data before inhibition was observed was 
fitted to the Michaelis-Menten equation: 
V = 
CK
CV
m +
max  
where V, Vmax, Km, and C represent the sulfation rate, maximal sulfation rate, the 
apparent Michaelis-Menten constant, and the utilized substrate concentration 
respectively. The IC50 values (inhibitor concentration at which sulfation rate is 50% 
of the controls) for 2,6,dichloro-4-nitrophenol were calculated from the Four-
Parameter Logistic Function as follows: 
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    y = D + 
BCx
DA
)log(101 −+
−
 
where x is the log concentration of the inhibitor and logC is the log of IC50. The IC50 
values for sodium chloride and the temperature at which enzyme activity was 
inhibited by 50% were calculated from the Four-Parameter Logistic Function (Linear) 
as follows: 
 
y = D + 
BCx
DA
)log)(log(101 −+
−
 
where x is the concentration of the inhibitor and logC is the log of IC50. Regression 
was performed using the Sigma Plot software (SPSS, Chicago, IL).  
 
2.3 Results  
2.3.1 Sulfotransferase mRNA expression in trophoblasts 
RT-PCR was performed to compare mRNA expression between BeWo cells and 
primary cytotrophoblasts. As can be seen in Figures 2.1 and 2.2, SULT1A3 and 
SULT1A1 were detected in both BeWo cells and cytotrophoblasts. The results 
indicated that SULT1A1 was upregulated in BeWo. SULT2A1 was expressed only in 
BeWo and not in the primary cytotrophoblast cells; SULT1E1 expression in BeWo 
was weak whereas it was undetectable in the cytotrophoblasts.  
 
The mRNA of another isoform, SULT1A2, has been detected in several human 
tissues but the protein is expressed at very low levels [27]. This isoform exhibits 96% 
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homology to SULT1A1 and 90% homology to SULT1A3 at the amino acid level. The 
recombinant protein exhibits biochemical properties very similar to SULT1A1. The 
primers used for SULT1A2 were not unique to it but could amplify any of SULT1A 
mRNAs (SULT1A1, SULT1A2, and SULT1A3) producing a 767 bp product. 
However, SULT1A2 has a recognition sequence for the restriction enzyme Hind III 
(cleaving the 767 bp product into 468 and 299 bp products) which is absent in both 
SULT1A1 and SULT1A3 [25]. On the other hand, both SULT1A1 and SULT1A3 
have recognition sequences for Sty I which would cleave them into 437 bp and 330 
bp, and 656 bp and 111 bp, products respectively. When the 767 bp product was 
subjected to Sty I restriction digest, bands were observed at 767 bp and 656 bp 
(Figure 2.4). No bands were observed at the expected positions for SULT1A1. Hind 
III digestion produced only the 767 bp band. This indicates that SULT1A2 mRNA is 
either not expressed in BeWo, or that SULT1A3 is expressed more abundantly and 
has been amplified at much higher levels than SULT1A2. However, the results raised 
doubts about the product obtained with the SULT1A1 specific primers (Figure 2.2). 
For confirmation this RT-PCR product was subjected to restriction digest by Sty I and 
fragments were observed at the expected positions (Figure 2.5). Further when this 
product was sequenced, it gave a good match to human liver SULT1A1 mRNA.  
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Figure 2.1 Reverse transcription polymerase chain reaction (RT-PCR) analyses 
of SULT1A3 and SULT2A1 in BeWo cells and in primary cytotrophoblast cells. 
200 ng mRNA was used for reverse transcription and polymerase chain reaction 
amplification of SULT2A1 and SULT1A3. Expected sizes: SULT1A1 (987 bp), 
SULT2A1 (872 bp). 
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Figure 2.2 Reverse transcription 
polymerase chain reaction (RT-PCR) 
analysis of SULT1A1 in BeWo cells 
and in primary cytotrophoblast cells. 
200 ng mRNA was used for reverse 
transcription and polymerase chain 
reaction amplification of SULT1A1. 
Expected size: SULT1A1 (987 bp). 
Figure 2.3 Reverse transcription 
polymerase chain reaction (RT-PCR) 
analysis of SULT1E1 in BeWo cells and 
in primary cytotrophoblast cells. 200 ng 
mRNA was used for reverse transcription 
and polymerase chain reaction 
amplification of SULT1E1. Expected size: 
SULT1E1 (464 bp). 
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Figure 2.4 Reverse transcription 
polymerase chain reaction (RT-PCR) 
analysis of SULT1A cDNA in BeWo 
after restriction digest with either Sty I 
or Hind III. 200 ng mRNA was used for 
reverse transcription and polymerase 
chain reaction amplification using primers 
that can code for SULT1A1, SULT1A2, 
or SULT1A3 (referred to as SULT1A). 
RT-PCR products were subjected to 
restriction enzyme digestion with either 
Hind III or Sty I. Expected sizes: 
Undigested SULT1A cDNA (767 bp), Sty 
I digest of SULT1A1 (437 bp and 330 
bp), Hind III digest of SULT1A2 (468 bp 
and 299 bp), and Sty I digest of 
SULT1A3 (656 bp and 111 bp). 
Figure 2.5 Reverse transcription 
polymerase chain reaction (RT-PCR) 
analysis of SULT1A1 cDNA in BeWo 
after restriction digest with Sty I. 200 
ng mRNA was used for reverse 
transcription and polymerase chain 
reaction amplification of SULT1A1 
cDNA. The RT-PCR product was 
subjected to Sty I digestion. Expected 
sizes: Undigested SULT1A1 (987 bp), 
Sty I digest of SULT1A1 (437 bp and 
550 bp). 
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2.3.2 4-nitrophenol and dopamine sulfation activities in BeWo 
The enzyme activities of SULT1A1 and SULT1A3 were tested using the diagnostic 
substrates of these enzymes – 4-nitrophenol for SULT1A1 and dopamine for 
SULT1A3. Sulfation of both 4-nitrophenol (0.1-160 µM) and dopamine (0.1-80 µM) 
exhibited substrate inhibition at higher concentrations (Figures 2.6 and 2.7). Sulfation 
of 4-nitrophenol and dopamine by recombinant SULT1A1 and SULT1A3 
respectively have been reported to exhibit substrate inhibition at higher 
concentrations [28]. Our results indicated SULT1A1 and SULT1A3 mediated 
sulfation of 4-nitrophenol and dopamine in BeWo cells.  
 
The sulfation profiles before substrate inhibition were fitted to the Michaelis-Menten 
equation to obtain kinetic parameters. The Km and Vmax values have been listed in 
table 2.3. The apparent Km value obtained with 4-nitrophenol compared well with 
SULT1A1-mediated sulfation either in other tissues or with the recombinant protein 
[3, 22, 29, 30]. These studies have reported Km values of SULT1A1-mediated 
sulfation of 4-nitrophenol in the range 0.5-1 µM. In BeWo, the Km obtained with 
dopamine sulfation was 0.3-0.7 µM. Though typically SULT1A3-mediated sulfation 
of dopamine exhibits higher apparent Km values (3-10 µM) [22, 31], much lower Km 
values have also been observed (0.65 µM) [32]. These indicated the possibility of 
SULT1A1 and SULT1A3 being functional in BeWo. However, there can be 
overlapping substrate specificities between the SULT isoforms. Thus the sulfation 
activities were further characterized in the presence of inhibitors.  
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Figure 2.6 4-nitrophenol sulfation (pmol/min/mg protein) in BeWo cells as a 
function of 4-nitrophenol concentration (Figure 2.6a).  Figure 2.6b shows the data 
up to 5 µM and represents a fit to the Michaelis-Menten equation. Each point 
represents the mean ± S.D. of three determinations. Each assay was repeated at least 
twice and Km was 0.32 – 0.65 µM.  
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Figure 2.7 Dopamine sulfation (pmol/min/mg protein) in BeWo cells as a 
function of dopamine concentration (Figure 2.7a).  Figure 2.7b shows the data up 
to 10 µM and represents a fit to the Michaelis-Menten equation. Each point represents 
the mean ± S.D. of three determinations. Each assay was repeated at least twice and 
Km was 0.28 – 0.71 µM.  
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2.3.3 Effect of inhibitors 2,6-dichloro-4-nitrophenol (DCNP) and NaCl 
To verify whether 4-nitrophenol and dopamine sulfation were mediated by SULT1A1 
and SULT1A3 respectively, the inhibitory effects of 2,6-dichloro-4-nitrophenol 
(DCNP) and sodium chloride were tested. Typically SULT1A1 activity is more 
sensitive to inhibition by DCNP and sodium chloride, than SULT1A3. In BeWo cells, 
4-nitrophenol sulfation was more sensitive to inhibition by DCNP than dopamine 
sulfation, whereas both exhibited similar sensitivities to sodium chloride inhibition 
(Figure 2.8 and table 2.3). The IC50 value for 4-nitrophenol sulfation obtained with 
DCNP is similar to previously cited values [22, 30, 33, 34] but the IC50 obtained with 
sodium chloride is somewhat higher than that proposed in the literature that puts it 
between 80-100 mM [22, 30]. The IC50 values with DCNP and sodium chloride for 
dopamine sulfation agreed very well with references of SULT1A3-mediated sulfation 
of dopamine, which put the values between 0.4-0.6 mM and 180-340 mM 
respectively [22, 31].  
 
2.3.4 Thermal stability 
SULT1A1 and SULT1A3 exhibit differential thermal stability, and this has led to 
their nomenclature as thermostable and thermolabile phenolic sulfotransferase 
isoforms respectively. SULT1A1 has been reported to be 50% inactivated between 
43-44ºC while SULT1A3 is 50% inactivated between 38.5-40.5ºC [22, 31, 34]. 
Though there are discrepancies between studies with regards to the absolute values 
reported, SULT1A1 is relatively more thermostable than SULT1A3 [33]. In BeWo  
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Figure 2.8 Effects of inhibitors on sulfotransferase activities. (a) Effect of 2,6-
dichloro-4-nitrophenol (DCNP) on 4-nitrophenol (-o-) and dopamine (-o-) sulfation 
activities in BeWo. The SULT activity in the presence of an inhibitor was expressed 
as a percentage of the activity in the absence of an inhibitor. The IC50 values for 4-
nitrophenol and dopamine were between (0.04-0.1 µM) and (0.95-1.14 mM) 
respectively. (b) Effect of NaCl on 4-nitrophenol (-o-) and dopamine (-o-) sulfation 
activities in BeWo. The SULT activity in the presence of an inhibitor was expressed 
as a percentage of the activity in the absence of an inhibitor. The IC50 values for 4-
nitrophenol and dopamine were between (300-360 mM) and (200-340 mM) 
respectively. Each point represents mean ± S.D. of three determinations. 
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Figure 2.9 Thermal stability of 4-nitrophenol and dopamine sulfation activities 
in BeWo. The net sulfotransferase activity was expressed as a percentage of the basal 
(unheated) activities. The 50% inactivation temperatures (T50) were 41.2-43.6ºC and 
39ºC for 4-nitrophenol and dopamine respectively. Each point represents mean ± S.D. 
of three determinations. 
 
Table 2.3 Kinetic parameters obtained from 4-nitrophenol and dopamine 
sulfation in BeWo cells in the absence and presence of inhibitors. 
 
 Substrate 
 4-nitrophenol Dopamine 
   
Km (µM) 0.32 – 0.65 0.28 – 0.71 
Vmax (pmol/min/mg) 6.9-10.94 5.9-10.4 
IC50 (DCNP, µM) 0.04-0.1 943-1135 
IC50 (NaCl, mM) 305-360 197-338 
T50 (ºC) 41.2-43.6 39 
 
cells, 4-nitrophenol and dopamine sulfation were 50% inactivated between 41-43ºC 
and at 39ºC, respectively (Figure 2.9 and table 2.3). These observations matched well 
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with previously reported values and indicated that in BeWo the enzymes retain 
distinctive thermal stability properties.  
 
Overall, the results of 4-nitrophenol and dopamine sulfation in the presence of 
inhibitors and heat, agreed well with previous reports [22, 30, 31, 33, 34]. As these 
results confirmed that 4-nitrophenol and dopamine sulfation in BeWo were mediated 
by SULT1A1 and SULT1A3 respectively, protein expression of these two enzymes 
was not examined in BeWo. 
 
2.3.5 17β-estradiol and dehydroepiandrosterone sulfation activities in BeWo 
SULT1E1 activity was assessed with 10-30 nM 17β-estradiol in BeWo cells. The 
sulfation rate (0.02-0.05 pmol/min/mg) observed was much lower than SULT1A1 or 
SULT1A3 activities. Genistein is a potent inhibitor of SULT1E1-mediated sulfation 
of 17β-estradiol [35]. In BeWo cells, 17β-estradiol sulfation was not inhibited by 
genistein indicating that 17β-estradiol sulfation is probably not mediated by 
SULT1E1 (Figure 2.10). This combined with the low mRNA levels of SULT1E1 
indicates that SULT1E1 is likely not functional in BeWo cells. 
 
It has been reported that SULT2A1 exhibits maximal activity towards DHEA at 3-10 
µM [4]. Even though the RT-PCR results indicated abundant expression of SULT2A1 
mRNA, there was negligible sulfation of DHEA (3 µM and 10 µM). Increasing 
protein concentrations did not increase DHEA sulfation. Under the same conditions 
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sulfation was observed with the recombinant protein. In Western blot (Figure 2.11) no 
band was observed at 35 kDa (molecular mass of SULT2A1). The native form of the 
enzyme is present as a homodimer and there are reports of both forms of the enzyme 
being observed in immunoblots [36]. Our experiments consistently revealed a band at 
75 kDa raising the possibility of this being a SULT2A1 dimer. Including reducing 
agents or eliminating  boiling (the latter has been said to cause SULT2A1 protein 
aggregation) [36] did not produce any change in western blot results, indicating that 
the 75 kDa band likely results from nonspecific antibody binding.  
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Figure 2.10 Sulfation of 17β-estradiol (10, 20, and 30 nM) in BeWo cells in the 
presence of genistein. Increase concentrations of genistein did not produce any 
change in 17β-estradiol sulfation.  
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Figure 2.11 Western blot analysis of SULT2A1 in BeWo cells. 40/80 µg of total 
protein from BeWo cell lysate and 2.5 µg of recombinant SULT2A1 protein were 
subjected to electrophoresis on a 12% Tris-glycine gel. The membrane was incubated 
with a SULT2A1 polyclonal antibody. The secondary antibody was peroxidase-
conjugated AffiniPure goat anti-rabbit IgG. The membrane was detected by 
chemiluminescence. Lanes 1, 2: 40 µg BeWo lysate with and without boiling; lanes 3 
and 4: 40 µg BeWo lysate + dithiothreitol (DTT) without boiling; lanes 5 and 6: 40 
µg BeWo lysate + DTT with boiling; lane 7: 80 µg BeWo cell lysate; lane 8: 2.5 µg 
of recombinant SULT2A1; lane 9: molecular weight marker. 
 
2.3.6 SULT1A1 and SULT1A3 activities in primary cytotrophoblast cells 
SULT1A1 and SULT1A3 activities were then examined in cytotrophoblast cells in 
the presence of 2,6,dichloro-4-nitrophenol (DCNP) concentrations that previously 
completely inhibited enzyme activities in BeWo cells (Figure 2.12). At these 
concentrations of DCNP (1 mM and 4 mM), sulfation of 4-nitrophenol and dopamine 
were also completely inhibited in cytotrophoblast cells. This indicated that 4-
nitrophenol sulfation and dopamine sulfation were being mediated by SULT1A1 and 
SULT1A3 respectively in the primary cytotrophoblast cells. SULT1A3 activity was 
similar in the two types of trophoblast (6.9±0.6 pmol/min/mg in BeWo cells vs. 
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3.8±0.8 pmol/min/mg in primary cytotrophoblast cells) whereas SULT1A1 was 
upregulated in BeWo cells (21.6±2 pmol/min/mg in BeWo cells vs. 2.8±2.4 
pmol/min/mg in the primary cytotrophoblast). The relative pattern of enzyme 
activities agreed with the mRNA expression of SULT1A1 and SULT1A3.   
 
2.4 Discussions and conclusions 
Placental metabolic enzymes mediate the synthesis and metabolism of hormones, as 
well as the metabolism of foreign chemicals that include medicinal drugs and 
environmental chemicals [37]. They can also produce carcinogenic adducts. For 
example, benzo(a)pyrene-7,8-diol-9,10-epoxide DNA adducts were found in the 
placenta of smokers [38]. The activation of benzo(a)pyrene to these carcinogenic 
adducts is mediated by CYP1A1 and CYP1A1 is active in the placenta throughout 
pregnancy. This underscores the importance of studying placental metabolism to not 
only reduce the extent to which a particular drug reaches the fetus but also to prevent 
toxic metabolites from reaching the fetus. Placental sulfation includes endogenous 
substrates (e.g., 17β-estradiol and 3,3’-triiodothyronine) and drugs (e.g., salbutamol, 
ritodrine, fenoterol, and betanaphthol) [39, 40]. Studies have indicated 
sulfotransferase activities in several sections of whole placental tissue but not much 
work has dealt with activities at the cellular level, which constitutes the rate-limiting 
barrier to trans-placental transfer [14]. Tamura et al. reported SULT1A1 and 
SULT1A3 enzyme activities in BeWo cells using single concentrations of the 
diagnostic substrates 4-nitrophenol and dopamine [18]. However, several  
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Figure 2.12 4-nitrophenol (4 µM) and dopamine (1 µM) sulfation activities in 
BeWo cells and primary cytotrophoblasts. Sulfotransferase activities were 
measured in the presence and in the absence of 1 mM and 4 mM 2,6,-dichloro-4-
nitrophenol (DCNP). At these concentrations, DCNP previously completely abolished 
4-nitrophenol and dopamine sulfation in BeWo cells.   
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sulfotransferase isoforms exhibit overlapping substrate specificity. For instance, 
SULT1A1, SULT1A2, and SULT1B1, all sulfate 4-nitrophenol at low micromolar 
concentrations and using single substrate concentrations can lead to erroneous 
identification of sulfotransferase isoforms [3, 41]. Our work examines 4-nitrophenol 
and dopamine sulfation activities in the presence of prototypical inhibitors of these 
enzymes and adds on to the work of Tamura et al [18]. Biochemical characteristics, 
including apparent Km values, response to inhibitors and thermal stability profiles 
agreed well with previously reported values. This led to the conclusion that 4-
nitrophenol and dopamine sulfations in BeWo cells are being mediated by SULT1A1 
and SULT1A3, respectively. When compared to the primary cultures of 
cytotrophoblast cells, enzyme activities indicated similar SULT1A3 activity in BeWo 
and the cytotrophoblasts, while SULT1A1 appeared to be upregulated in BeWo cells. 
This is consistent with the RT-PCR results that revealed similar SULT1A3 mRNA 
levels but elevated SULT1A1 mRNA in BeWo cells. The enzyme activity assays and 
western blots indicated that SULT2A1 protein is not expressed in BeWo cells. 
Although SULT2A1 mRNA was abundantly expressed in BeWo cells it was not 
expressed in cytotrophoblasts. This indicates that this enzyme is probably not active 
in trophoblast cells. There appears to be some contradiction about the expression of 
SULT2A1 in placenta. Stanley et al reported high sulfation rates of DHEA in 
fractions rich in syncytiotrophoblasts and attributed this to SULT2A1. However, 
Nishimura et al failed to detect any SULT2A1 mRNA in the placenta [12, 14]. In the 
work of Stanley et al. DHEA sulfation was detected with 10 µM DHEA. However, 
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SULT2A1 is not the only isoform that sulfates DHEA at such concentrations. 
Another sulfotransferase isoform SULT2b1b, which also sulfates hydroxysteroids, is 
localized primarily to the nuclei of syncytiotrophoblasts [42]. One of the 
physiological substrates of SULT2b1b is cholesterol [7] which is a precursor for 
progesterone synthesis. The placenta synthesizes progesterone and it has been 
speculated that the physiological role of SULT2b1b in the placenta may be prevention 
of nuclear receptor activation [43]. SULT2b1b and SULT2A1 exhibit similar 
affinities for DHEA [42]. It is possible that the DHEA sulfation activity reported by 
Stanley et al. [14] was mediated by SULT2b1b. Another possible reason for the 
discrepancy observed in our work and the work of Stanley et al. [14] with respect to 
SULT2A1 function in trophoblast, could be differential enzyme expression between 
the cytotrophoblasts and syncytiotrophoblasts which has been observed with several 
transport proteins [44]. BeWo cells consist primarily of cytotrophoblasts while 
Stanley et al. used placental sections predominantly consisting of 
syncytiotrophoblasts [14].  
 
Our results indicated that SULT1E1 is not expressed in BeWo cells. Like SULT2A1 
there are conflicting reports on placental SULT1E1 expression. In placental fractions 
rich in syncytiotrophoblasts, SULT1E1 activity was much lower than SULT1A1 and 
SULT1A3 activities [14]. It has also been reported that SULT1E1 mRNA in placenta 
is lower by 40 fold or more than SULT1A1 or SULT1A3 mRNA [12]. On the other 
hand some studies have reported SULT1E1 to be localized to syncytiotrophoblasts 
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[17]. One possible reason for observing low SULT1E1 activity in BeWo cells could 
be the presence of steroid sulfatase enzymes. These enzymes exhibit particularly high 
activity in placental tissue and have been localized to the syncytiotrophoblasts [17, 
45].  
 
Overall this study indicates that the phenolic sulfotransferase isoforms SULT1A1 and 
SULT1A3 are active in trophoblast cells. SULT1A1 sulfates a wide range of 
substrates that includes steroid hormones, medicinal drugs, as well as procarcinogens. 
Not much has been reported on the physiological functions of this enzyme in the 
placenta. Previously Stanley et al. failed to find any correlation between placental 
SULT1A1 and SULT1A3 activities and thyroid hormone sulfation which led them to 
conclude that placental sulfation is most likely not responsible for the high levels of 
T3 and T4 sulfate detected in the fetal circulation [14]. One of the endogenous 
substrates of SULT1A1 is 17β-estradiol, although SULT1A1 sulfates the hormone at 
much higher concentrations than SULT1E1 [46]. As the syncytiotrophoblast secretes 
increasing amounts of the 17β-estradiol with advancing gestation [47], it is tempting 
to speculate that a possible physiological function of the enzyme is maintaining tissue 
estrogen balance, at least under conditions of high local concentrations.  
 
Endogenous substrates of SULT1A3 include catecholamines (e.g., epinephrine, 
norepinephrine and dopamine) and catecholestrogens. The majority of plasma 
catecholamines exist in the sulfated form. While circulating levels of epinephrine and 
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norepinephrine sulfate levels are around 70-80%, ~95% of circulating dopamine 
exists in the sulfated form [48]. In patients suffering from hypertension, plasma levels 
of dopamine sulfate were elevated without any change in the free levels of dopamine, 
and it has been speculated that genetic defects in the aryl sulfatase gene may cause 
essential hypertension [49, 50]. In  pheochromocytoma, there is an elevation in the 
plasma levels of catecholamines as well as the catecholamine sulfates [51]. The 
physiological significance of catecholamine sulfation is not very well understood. 
Since sulfated catecholamines are inactive at the adrenergic and dopaminergic 
receptors, it has been suggested that conjugation serves as a protective mechanism 
against the adverse responses that may be produced from the high circulating levels 
of catecholamines [7, 52-55]. While studies have not dealt with the role of SULT1A3 
in the placenta, similar to its function in other tissues, physiological functions of 
SULT1A3 in the placenta may be catecholamine inactivation. 
 
Sulfation is well developed in the fetus. Several studies report fetal hepatic SULT1A1 
activity (~100-150 pmol/min/mg protein) to be higher than placental activity (~ 20-40 
pmol/min/mg protein) [16, 56]. Activities in fetal kidney and adrenal were similar or 
higher than that in the placenta. Similarly, SULT1A3 activities in fetal gut and liver 
were respectively 10- and 5- fold higher than that in the placenta [16, 56]. No 
correlations were found between gestational age (14-35 weeks) and fetal 
sulfotransferase activity suggesting that fetal sulfation had developed by the 14
th
 
week of gestation [16]. Nevertheless, the SULT1A family also appears to be well 
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developed in the placenta and likely acts as a support of fetal metabolism for fetal 
protection. 
 
In conclusion our work establishes the phenolic sulfotransferase isoforms SULT1A1 
and SULT1A3 to be functional in BeWo cells and in primary cultures of 
cytotrophoblast cells. A lot of the work on placental metabolism has focused on the 
effects of cigarette smoke, medicinal drugs, and environmental chemicals on 
placental enzyme activity, as a way of determining if this may be related to fetal 
toxicity. There has not been a lot of focus on the effects of foreign chemicals on 
placental sulfotransferase activity. SULT1A1 catalyses the sulfation of several 
procarcinogens such as N-hydroxylated aromatic amines, nitroalkanes, and benzylic 
alcohols to produce nucleophilic DNA adducts [57, 58]. The functional activities of 
SULT1A1 and SULT1A3 in BeWo cells suggests that this cell line can be used as a 
suitable model for studying placental sulfotransferase induction/inhibition as a basis 
for developing an understanding of the role of these enzymes in physiological and 
disease processes.  
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Chapter 3: Effect of Chronic Bisphenol A Exposure on SULT1A1 
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3.1 Introduction 
Bisphenol A is widely used in the production of polycarbonate plastics that are used 
in the manufacture of food and beverage containers, and epoxy resins that are used in 
linings of metal food and beverage cans, and dental sealants. Bisphenol A is 
manufactured in large quantities with its annual production capacity exceeding 6 
billion pounds in 2003 [1]. The ester bonds linking the monomers of bisphenol A in 
polycarbonate plastics and resins are hydrolyzed to release bisphenol A. The reaction 
is accelerated under acidic conditions, basic conditions, and increasing temperature[1, 
2]. Leaching increases with repeated use. Human exposure to bisphenol A is believed 
to be mainly through food [3]. Mean bisphenol A concentrations in random serum 
samples of the human population following environmental exposure are estimated to 
be in the range 0.6-2.5 ng/mL [4-7].  Pregnancy does not seem to affect bisphenol A 
disposition as serum concentrations of bisphenol A in women from early pregnancy 
did not significantly differ from that of non-pregnant women [8]. Similar levels of 
bisphenol A in fetal and maternal serum indicate that bisphenol A readily crosses the 
placenta [8, 9]. Median placental concentrations of bisphenol A are approximately 
12.7 µg BPA/kg of placental tissue (range 1-105 µg/kg) [9].   
 
Although nonsteroidal in structure (Figure 3.1.1) bisphenol A mimics the actions of 
17β-estradiol and is considered to be a xenoestrogen [10-12]. Bisphenol A binds to 
the nuclear estrogen receptors (ER) α and β, and plasma membrane-bound ERs [11, 
13]. It is also considered to be an endocrine disrupter as neonatal or prenatal 
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bisphenol A exposure produces severe reproductive tract abnormalities in rodents. 
Some effects observed in female mice include morphological and functional changes  
 
 
 
 
   
 
  
 
 
Bisphenol A 17β-estradiol 
 
Figure 3.1.1 Structures of bisphenol A and 17β-estradiol. 
 
in the ovaries, mammary glands, brain, and reproductive tract [14-16]. In male 
rodents prostate enlargement, alterations in prostate histoarchitecture, and increased 
expression of the androgen receptor constitute some of the consequences of perinatal 
BPA exposure [16]. Maffini et al have documented the effects observed in rodents 
after perinatal exposure to bisphenol A as shown in Figure 3.1.2 [16]. Some of the 
above-mentioned in vivo effects of bisphenol A were from doses that resulted in 
plasma concentrations similar to that reported in humans following environmental 
exposure [15]. Thus there is growing concern over bisphenol A exposures posing a 
potential threat to human health, especially during organogenesis. Similarly in in vitro 
studies, effects of bisphenol A included cell proliferation in prostatic adenocarcinoma 
cells, breast cancer cells, and increased prolactin release (which can be linked to 
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reproductive dysfunctions) in rat pituitary cells  [10, 13, 17]. Bisphenol A produced 
some of these effects at concentrations relevant in humans.  
 
 
Figure 3.1.2 Effects of perinatal exposure to bisphenol A in rodents (The figure 
has been adapted from Maffini et al., Mol Cell Endocrinol, 2006. 254-255: p. 179-
86). 
 
In chapter 1 we established the functional activity of the sulfotransferase isoforms 
SULT1A1 and SULT1A3 in the BeWo cell line. Estrogenic compounds acutely 
inhibit both SULT1A1 and SULT1A3, but they inhibit SULT1A1 with a much higher 
potency [18, 19]. Although there is much less information available on the effect of 
estrogenic substances on sulfotransferase enzymes upon chronic exposure, it has been 
demonstrated that when breast cancer cells were treated with 4-hydroxy-tamoxifen 
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for 16 hours, of the 8000 transcripts analyzed only members of the SULT1A family 
were upregulated [20]. Estradiol also increased SULT1A mRNA levels, although at 
longer periods of incubation (72 hours). So, taking into account firstly that SULT1A1 
is potently inhibited by estrogenic substances; secondly that bisphenol A achieves 
appreciable placental concentrations and is estrogenic, it would be interesting to 
observe if bisphenol A produces any effects on SULT1A1 activity in the trophoblast. 
The objective of this study was to determine the effect of bisphenol A on SULT1A1 
activity in trophoblasts upon acute as well as chronic exposure. We have used the 
BeWo cell line as a trophoblast model. 
 
3.2 Materials and methods 
3.2.1 BeWo cell culture 
The BeWo cell line (clone b30) was obtained from Dr. Alan Schwartz (Washington 
University, St. Louis, MO) and cultured as described previously [21]. Passages 29 
through 45 of the cells were used in this study. Briefly, cells were grown at 37ºC in an 
atmosphere of 5% CO2 and 95% relative humidity. They were maintained in 
Dulbecco’s Modified Eagles Medium (DMEM, Sigma, St. Louis, MO) containing 
10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), and 1% 
each of 10,000 U/ml penicillin with 10,000 µg/mL streptomycin, 200 mM L-
glutamine, and 10 mM minimal essential medium nonessential amino acid solution 
(all three from Invitrogen, Carlsbad, CA). At 70-90% confluence, cells were detached 
with 0.5% trypsin and 0.2% ethylenediaminetetraacetic acid solution (EDTA, Sigma, 
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St. Louis, MO) diluted in phosphate buffered saline (PBS) at a 1:10 ratio. Cells were 
then subcultured at a ratio of 1:10. 
 
3.2.2 Cell lysate preparation  
BeWo cell lysate was prepared as per the protocol of Ebmeier et al with a few 
modifications [22]. Cells at 90-100% confluence were washed and scraped up in 
prewarmed (37ºC) PBS containing 0.5 mM ethylenediaminetetraacetic acid (EDTA, 
Sigma, St. Louis, MO) and 1 mM phenylmethanesulfonylfluoride (PMSF, Sigma, St. 
Louis, MO). They were then centrifuged, PBS was aspirated off, and the cells were 
homogenized in 5 mM potassium phosphate (pH 7.4), containing 0.25 M sucrose, 
1.25 mM tetrasodium EDTA, 1.5 mM dithiothreitol (all from Sigma, St. Louis, MO), 
and Complete Mini Protease inhibitor cocktail (Roche, Indianapolis, IN) at 4ºC for 20 
strokes using a Dounce homogenizer. Homogenates were centrifuged at 13,000 x g 
for 20 minutes at 4ºC. The resultant supernatant was further centrifuged at 100,000 x 
g for 1 hour at 4ºC. Aliquots of the resulting supernatant were used for protein 
determination using the Bradford protein assay method (Biorad, Hercules, CA). The 
remaining supernatant was mixed with an equal volume of 5mM potassium phosphate 
(pH 7.4), containing 5 mg/ml BSA (Sigma, St. Louis, MO) and was stored at -80ºC 
until further use.   
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3.2.3 Chronic treatment of BeWo cells with bisphenol A  
Bisphenol A (Sigma, St. Louis, MO) was prepared as 1000x stock solutions in 
ethanol. Cells were plated at a density of 10,000 cells/cm
2
. For the 48 hour 
treatments, cells at ~ 50% confluence were exposed to selected concentrations of 
bisphenol A. The medium was changed 24 hours later and BPA was included in the 
change medium at the same concentration. Control cells were cultured in medium 
containing 0.1% ethanol under the same conditions. Bisphenol A treatments were 
performed either in serum-containing or serum-free medium. For the 24 hour 
treatments, cells were exposed to the selected concentrations of bisphenol A in 
serum-free medium at ~70% confluence. At the end of the dosing period, homogenate 
was prepared and stored as outlined in section 3.2.2. Incubations with the estrogen 
receptor inhibitor ICI 182,780 (Tocris Bioscience, Ellisville, MO) were all done in 
serum-free medium for a period of 24 hours.   
 
3.2.4 Determination of SULT1A1 activity 
Sulfotransferase enzyme assays were performed using 4-nitrophenol as a marker 
substrate of SULT1A1. The enzyme assay was a modification of the method of 
Foldes and Meeks [23]. The final reaction mixture consisted of substrate 4 µM 4-
nitrophenol (Sigma, St. Louis, MO), 1 µM [
35
S] PAPS (Perkin Elmer, Waltham, 
MA), and 5 µg BeWo cytosolic protein in 50 mM potassium phosphate buffer (pH 
7.4). Control reactions contained DMSO (Sigma, St. Louis, MO) in place of the 
substrate. The reaction mixture was incubated at 37
o
C for 20 minutes. The reaction 
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was terminated by adding 0.1 M barium hydroxide (Sigma, St. Louis, MO), 0.1 M 
barium acetate (Sigma, St. Louis, MO), and 0.1 M zinc sulfate (Sigma, St. Louis, 
MO) to precipitate the enzyme and the unreacted [
35
S]PAPS. The sulfated product 
was determined by liquid scintillation counting. Each assay was performed at least in 
duplicate. Enzyme assays measuring the acute inhibitory effect of bisphenol A on 
SULT1A1 were performed in a similar manner. The reaction mixtures contained both 
4-nitrophenol and bisphenol A, whereas the controls contained bisphenol A alone.  
 
3.2.5 Reverse transcription polymerase chain reaction (RT-PCR) 
BeWo cells at confluence were washed, scraped in PBS, and then centrifuged to 
remove the PBS. Total RNA was isolated using a commercially available phenol-
guanidine isothiocyanate solution (TRIZOL Reagent, Invitrogen) according to the 
manufacturer’s protocol. mRNA was purified from total RNA using an Oligotex 
mRNA Mini Kit (Qiagen, Valencia, CA) as per the manufacturer’s protocol and 
stored at -80ºC until further use. The mRNA was concentrated prior to the experiment 
by mixing the required volume (containing 200 ng RNA) with 1/10
th
 the volume of 3 
M DEPC treated sodium acetate (pH 5.2),  2 µL glycogen (Roche Diagnostics, 
Indianapolis, IN), and ethanol (at a volume 2.5 fold more than the volume of mRNA). 
This was stored overnight at -20ºC to precipitate the mRNA. After overnight 
precipitation, the sample was spun down at 14,000 rpm for 15 minutes at 4ºC. The 
supernatant was aspirated off, the pellet was washed in 75% ethanol, and the tubes 
spun down at 14,000 rpm for 15 minutes at 4ºC. Most of the supernatant was 
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aspirated off. The remainder was dried in room air and reconstituted in RNAse free 
water prior to reverse transcription. 200 ng mRNA was reverse transcribed and 
amplified using the Access RT-PCR Introductory System (Promega, Madison, WI). 
The primer sequences for amplifying SULT1A1 were obtained from the literature 
[24]. The sense primer for SULT1A1 was 5’-ATGGAGCTGATCCAGGACAC-3’ 
and the antisense primer was 5’-TGACCTACCGTCCCAGGCCC-3’. Primers were 
synthesized by the Biotechnology Support Facility at the University of Kansas 
Medical Center (Kansas City, KS). The primers utilized for amplifying β-actin 
transcripts were obtained from Promega (Madison, WI). Cycle parameters were as 
follows: 1 cycle each of reverse transcription at 48
o
C for 45 minutes and denaturation 
for 2 min at 94 °C, followed by 40 cycles each of denaturation at 94
o
C for 30 
seconds, annealing at 60
o
C for 1 minute, and extension at 68
o
C for 2 minutes. This 
preceded a final elongation at 68°C for 7 minutes. Electrophoresis of all RT-PCR 
products was performed at 80 V on a 2% agarose gel. The gel was post-stained with 
0.5 µg/mL ethidium bromide for 45 minutes, washed four times in distilled water at 
10 minute intervals and viewed with a UV transilluminator.  
 
3.2.6 Cytotoxicity assays 
Cytotoxicity of bisphenol A was assessed using the Quick Cell Proliferation Assay 
Kit (Biovision, Mountain View, CA) according to manufacturer’s protocol. The assay 
measures cellular mitochondrial dehydrogenase mediated conversion of the 
tetrazolium salt WST-1 to formazan (which absorbs at 440 nm). Briefly, cells were 
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cultured on 96-well plates at a density of 10,000 cells/cm
2
,
 
in a total volume of 100 
µL. They were treated as mentioned in section 3.2.3. Following this 10 µL of the 
reagent was added to each well, the cells were incubated for 2 hours under standard 
culture conditions, and absorbance read at 450 nm.  
 
3.3 Results 
3.3.1 Bisphenol A as an acute inhibitor of SULT1A1  
Bisphenol A has been reported to be a substrate of SULT1A1 (Km=4.7 µM; specific 
activity = 965±206 pmol/min/mg protein at a concentration of 50 µM) [25, 26] . In 
BeWo cell homogenates, however, no sulfation could be detected using bisphenol A 
(0.6-100 µM) as a substrate (data not shown). Hence it can be assumed that under the 
utilized assay conditions if BeWo cytosolic protein was incubated with both 4-
nitrophenol and bisphenol A, the measured radioactivity would be due to 4-
nitrophenylsulfate and not bisphenol A sulfate. Bisphenol A (0.5-50 µM) was 
incubated along with 4 µM 4-nitrophenol. Bisphenol A significantly inhibited 
SULT1A1 only at 50 µM (Figure 3.3.1). Higher concentrations of bisphenol A were 
not tested because at 50 µM bisphenol A is at a much higher concentration than its 
concentrations detected in random human serum samples.  
 
3.3.2 Effect of chronic exposure to bisphenol A on SULT1A1 activity  
Upon chronic (48 hours) exposure, bisphenol A inhibited SULT1A1 at intermediate 
concentrations but not at lower or higher concentrations to produce a U-shaped non-
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monotonic dose-response curve (Figure 3.3.2). Inhibition was observed at 100pM – 1 
µM and was statistically significant at 10 nM and 100 nM. The maximal inhibition 
observed was around 40%. At none of the tested concentrations, bisphenol A affected 
cell viability (Figure 3.3.3). 
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Figure 3.3.1 Effect of acute bisphenol A exposure upon SULT1A1 activity. 
SULT1A1 activity in BeWo cytosolic homogenate was determined with 4 µM 4-
nitrophenol, in the absence and presence of bisphenol A at 37ºC. Control experiments 
contained bisphenol A at the same concentrations in the absence of 4-nitrophenol. 
The data has been plotted as mean ± S.E.M (n=3). * denotes a significant difference 
with respect to the vehicle-treated controls (p<0.05).  
* 
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Figure 3.3.2 Effect of chronic bisphenol A exposure upon SULT1A1 activity. 
BeWo cells were exposed to bisphenol A (10 pM-50 µM) in DMEM containing 10% 
fetal bovine serum for 48 hours. The cytosolic fraction of BeWo homogenate was 
then extracted and SULT1A1 activity was determined with 4 µM 4-nitrophenol at 
37ºC. The net SULT1A1 activity has been expressed as a percentage of the vehicle-
treated controls. Each data point in a particular experiment represents triplicate 
measurements and each experiment was repeated twice. The data has been plotted as 
mean ± S.E.M. * denotes a significant difference with respect to the vehicle-treated 
controls (p<0.05). 
* 
* 
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Figure 3.3.3 BeWo cell viability upon bisphenol A exposure. BeWo cells were 
seeded in 96-well plates. The cells were treated with bisphenol A (10 pM-50 µM) 
after 48 hours for the 48-hour treatments and after 72 hours for the 24-hour 
treatments. Treatments were either in serum-free or serum-containing medium. Upon 
completion of treatment, cytotoxicity was assessed by the WST assay (a modification 
of the MTT assay) using a commercially available kit. * denotes a significant 
difference with respect to the vehicle-treated controls (p<0.05). 
 
3.3.3 Effect of chronic exposure to bisphenol A on SULT1A1 mRNA expression.  
mRNA was extracted from BeWo cells after chronic exposure to bisphenol A for 48 
hours. Concentrations tested were 100 nM, 1 µM, and 50 µM. In accordance to what 
was observed with the enzyme activity assays, at concentrations of 1 µM and 50 µM, 
there was no change in SULT1A1 mRNA expression with respect to the vehicle-
treated controls (Figure 3.3.4). Contrary to what was observed with the enzyme 
activity data, there was no decrease in SULT1A1 mRNA at 0.1 µM.  
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Figure 3.3.4 Effect of chronic bisphenol A exposure on SULT1A1 mRNA 
expression. BeWo cells were exposed to bisphenol A (100 nM, 1 µM, and 50 µM) in 
DMEM containing 10% fetal bovine serum for 48 hours. mRNA was then isolated 
and RT-PCR was performed to detect SULT1A1 mRNA. Each data point in a 
particular experiment represents triplicate measurements. The data has been plotted as 
mean ± S.E.M.  
 
 
3.3.4 Effect of chronic exposure to bisphenol A on SULT1A1 activity (serum-free 
medium). 
The above-mentioned chronic bisphenol A incubations (section 3.3.2) were done in 
medium containing 10% serum. To eliminate any extra-estrogenic effects, BeWo 
cells were exposed to bisphenol A in medium without any serum for either 24 or 48 
hours. As with treatments in serum-containing medium, chronic bisphenol A 
exposure resulted in SULT1A1 activity inhibition producing a U-shaped non-
monotonic dose-response curve. Statistically significant inhibition was observed only 
at intermediate concentrations of 10 nM (Figure 3.3.5). SULT1A1 activity was 
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inhibited at lower and higher concentrations but this was not statistically significant.  
At these concentrations bisphenol A was not toxic to the cells (Figure 3.3.3). 
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Figure 3.3.5 Effect of bisphenol A on SULT1A1 activity upon chronic exposure 
to bisphenol A. BeWo cells were exposed to bisphenol A in serum-free medium for 
24 or 48 hours. The cytosolic fraction of homogenate was then extracted and 
SULT1A1 activity was determined with 4 µM 4-nitrophenol at 37ºC. The net 
SULT1A1 activity has been expressed as a percentage of the vehicle-treated controls. 
Each data point in a particular experiment represents triplicate measurements and 
each experiment was repeated twice. The data has been plotted as mean ± S.E.M. * 
denotes a significant difference with respect to the vehicle-treated controls (p<0.05). 
  
 
3.3.5 Effect of ICI182,780 on bisphenol A mediated inhibition of SULT1A1 
To determine if the inhibitory effect of bisphenol A was mediated through ERβ, 
BeWo cells were exposed to 10 nM bisphenol A in the absence or presence of 
IC182,780 (10 nM, 100 nM, 1 µM) in serum-free medium for 24 hours. At these 
concentrations ICI182,780 has previously been shown to inhibit ERβ. If bisphenol A 
* * 
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mediated inhibition of SULT1A1 is via ERβ, then in the presence of ICI182,780 
SULT1A1 activity should come back to the levels of the untreated controls. Even in 
the presence of ICI182,780 SULT1A1 activity was inhibited to the same extent 
indicating that at least the inhibitory effect of bisphenol A on SULT1A1 was not 
mediated through ERβ (Figure 3.3.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.6 Effect of bisphenol A on SULT1A1 activity in the presence of 
ICI182,780. BeWo cells were exposed to 10 nM bisphenol A (BPA) in the 
presence/absence of the estrogen receptor inhibitor ICI182,780 in serum-free medium 
for 24 hours. The cytosolic fraction of homogenate was then extracted and SULT1A1 
activity was determined with 4 µM 4-nitrophenol at 37ºC. The net SULT1A1 activity 
has been expressed as a percentage of the vehicle-treated controls. The data has been 
plotted as mean ± S.E.M (n=3). * denotes a significant difference with respect to the 
vehicle-treated controls (p<0.05). 
 
 
Co
nt
ro
l
BP
A
BP
A 
+ 
10
 n
M
 IC
I1
82
,7
80
BP
A 
+ 
10
0 
nM
 IC
I1
82
,7
80
BP
A 
+ 
1 
µM
 IC
I1
82
,7
80
0
50
100
150
%
 S
U
L
T
1
A
1
 a
c
ti
v
it
y
* 
* 
* 
* 
 91 
3.4 Discussions and conclusions 
In many cases 4 µM 4-nitrophenol is used as a marker substrate for SULT1A1. We 
established in chapter 2 that sulfation of 4-nitrophenol in the low micromolar range in 
BeWo cells is mediated by SULT1A1. Therefore, 4 µM 4-nitrophenol was used to 
test for SULT1A1 activity. Bisphenol A inhibits SULT1E1 [27] but there are no 
reports of it being a SULT1A1 inhibitor. Upon acute exposure, bisphenol A inhibited 
SULT1A1 at 50 µM but not at lower concentrations. As mean serum concentrations 
of bisphenol A are approximately reported to be in the range 0.6-2.5 ng/mL (~1-12.5 
nM), bisphenol A is not an acute inhibitor of SULT1A1 at concentrations at which it 
was detected in random samples of the human population following environmental 
exposure. This data agrees with previous reports regarding bisphenol A as an 
inhibitor of other enzymes (i.e. inhibition is observed only at concentrations much 
higher than relevant concentrations). For example, bisphenol A inhibited SULT1E1 at 
1 µM or higher concentrations. It also inhibits several cytochrome P450 enzymes. 
However in most of these cases, the reported IC50 values were all higher than the 
serum concentrations of bisphenol A [28, 29].  
 
In contrast to the acute exposure studies, bisphenol A inhibited SULT1A1 activity 
upon chronic exposure at relevant concentrations. Dose-dependent inhibition was not 
observed, rather a U-shaped non-monotonic dose-response curve was seen. 
Statistically significant inhibition was observed at 10 nM and 100 nM, and the 
maximal inhibition was approximately 40%. In contrast to SULT1A1 activity, 
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bisphenol A did not affect SULT1A1 mRNA expression, which suggested that the 
effects of bisphenol A on SULT1A1 were likely post-translational.  
 
Initial experiments were conducted in serum-containing medium. The effective 
concentration of bisphenol A as well as any other exogenous compound is dependent 
on protein binding to serum proteins as this modifies the amount available for cellular 
uptake. Bisphenol A is reported to have a free fraction of ~8% in serum [30]. 
Therefore we hypothesized that it should inhibit SULT1A1 with a higher potency in 
serum-free media. In serum-free medium, bisphenol A inhibited SULT1A1 to 
approximately the same extent (the maximum inhibition observed was around 30%) 
and in a similar manner, to produce a U-shaped dose-response curve. Statistically 
significant inhibition was observed only at intermediate concentrations (~10 nM). 
The same extent of inhibition was observed for either 24 or 48 hour incubations. The 
U-shaped nature of the curve indicates that bisphenol A is acting through at least two 
mechanisms. One pathway inhibits SULT1A1 activity while the other induces 
SULT1A1 activity. The combined effect produces a U-shaped curve. Such non-
monotonic dose-response curves have been observed for other estrogenic substances. 
For example, to test the estrogenicity of several phytoestrogens and environmental 
estrogens, estrogenic induction of pS2 mRNA was determined in MCF-7 breast 
cancer cells following incubation of the cells with testosterone. Several of the 
compounds tested produced U-shaped dose-response curves. The effect was proposed 
to be due to the phytoestrogens acting through two pathways – at lower 
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concentrations, the phytoestrogens inhibited aromatase activity (which led to a lesser 
amount of 17β-estradiol being produced from testosterone) whereas at higher 
concentrations pS2 mRNA was induced through the estrogenicity of the 
phytoestrogens [31].  
 
Bisphenol A exerts some of its effects by binding to the nuclear estrogen receptors 
(ER) α and β. The resulting complex binds to estrogen responsive elements (EREs) 
on genes to affect transcription. The nuclear estrogen receptor mediated effects of 
BPA are cell specific as it depends on the type and the levels of the receptor type 
expressed in each cell. Bisphenol A binds to ERβ with a higher affinity than it does to 
ERα. Also, the ERβ-bisphenol A complex recruits some co-activators with a greater 
affinity than the ERα-bisphenol A complex. Further, each has several isoforms and 
the different isoforms of ERβ  differentially affect ERE-dependent gene expression 
[32]. In addition to these nuclear receptor mediated effects, some of the rapid 
signaling effects produced by bisphenol A are mediated through the non-classical 
membrane estrogen receptor (ncmER) [32]. 
  
Not much is known about the transcriptional regulation of SULT1A1 in humans. 
Glucocorticoids induce SULT1A1 mRNA and protein in bovine adrenocortical cells, 
as well as in rat (both in vitro and in vivo). In rat hepatocytes, transcriptional 
induction of SULT1A1 is mediated through both the glucocorticoid receptor (GR) as 
well as the androgen receptor (AR), with GR mediation predominating over AR 
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mediation [33]. However, human hepatic SULT1A1 expression is not affected by 
glucocorticoid treatment [33]. Activators of other nuclear receptors such as the 
constitutive androgen receptor (CAR), pregnane-X receptor (PXR), and the aryl 
hydrocarbon receptor (AhR), also did not alter SULT1A1 mRNA levels in primary 
human hepatocytes [34].  
 
The BeWo b30 subclone used in this study expresses the estrogen receptor β (ERβ) 
but not ERα [35, 36]. The U-shaped curve indicates that bisphenol A is possibly 
acting through at least two mechanisms. One of these inhibits SULT1A1 activity 
while the other induces SULT1A1 activity, and the combined effect results in a U-
shaped curve. The presence of the ERα and ERβ inhibitor ICI182,780 did not produce 
any change in inhibitory effect observed with 10 nM bisphenol A. The inhibitory 
effect reaches a maximum around 10-100 nM. If this effect is mediated by ERβ, then 
in the presence of ICI182,780 SULT1A1 activities should be higher than that in the 
presence of bisphenol A alone. The lack of any effect of ICI182,780 indicates that at 
least the inhibitory effect of bisphenol A on SULT1A1 is not mediated through ERβ. 
Future studies should examine whether ERβ is associated with the up-regulation of 
SULT1A1 activity. If the increase in SULT1A1 activity that is observed at bisphenol 
A concentrations greater than 10-100 nM, is not observed in the presence of 
ICI182,780, then this would indicate that the inductive effect of bisphenol A on 
SULT1A1 is being mediated through ERβ.  
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In conclusion, we can say that chronic exposure to bisphenol A inhibited SULT1A1 
at concentrations detected in random serum samples of the human population. The 
nature of inhibition suggested that bisphenol A is acting via at least two mechanisms, 
one of which inhibits SULT1A1 and the other induces SULT1A1. The inhibitory 
effect of bisphenol A on SULT1A1 was not mediated via ERβ. Altered SULT1A1 
activity can potentially modify fetal exposure to sulfotransferase substrates. It can 
also have other consequences such as changes in estradiol sulfation which is a 
SULT1A1 substrate. It has been proposed that, reduced estrogen sulfation by 
polymorphic variants of SULT1A1 that exhibit reduced enzyme activity, may be a 
possible cause of cancer in estrogen-responsive tissues [37]. On the other hand, the 
extent of SULT1A1 inhibition (~30-40%) was modest and may not translate into 
actually altering the extents of fetal exposure as sulfotransferase substrates can be 
subject to other conjugation pathways such as glucuronidation.  
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Chapter 4: Mechanisms of Elimination of Sulfate Metabolites out of BeWo Cells 
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4.1 Introduction 
The placenta has the capacity of promoting elimination of drugs and natural 
substances by sulfation [1, 2]. Since sulfate metabolites bear a negative charge at 
physiological pH it is likely that passive diffusion would not be the predominant 
mechanism of their elimination out of the placenta. This indicates transporter-
mediated elimination which can be mediated by either uptake transporters or efflux 
transporters.  
 
Among the efflux transporters, the breast cancer resistance protein (BCRP) mediates 
biliary elimination of sulfoconjugates in rat and mice [3, 4]. Similarly human BCRP 
mediated the elimination of steroid sulfate conjugates and the sulfate conjugates of 
smaller exogenous molecules in cell-based systems overexpressing this transporter 
[5-7]. A major part of the work regarding the involvement of multidrug resistance-
associated protein isoforms in the excretion of sulfate conjugates has been performed 
in rats where MRP2 excreted bile acid conjugates as well as xenobiotic sulfate 
conjugates [6]. MRP3 and MRP4 have been reported to interact with the sulfate 
conjugates of xenobiotics, steroids and bile acids, while MRP1 has been reported to 
transport steroid conjugates [6, 8]. Thus literature would suggest that MRP isoforms 
and BCRP are prime candidates to mediate the transport of sulfated metabolites.  
 
BCRP is abundantly expressed in the placenta with immunohistochemistry revealing 
predominantly syncytiotrophoblast staining with some staining of the fetal blood 
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vessels [9, 10].  As far as its syncytiotrophoblast localization is concerned, several 
studies have reported mainly brush border (maternal-facing) membrane localization 
with faint signals detectable in the basal (fetal-facing) membrane fractions [5, 11] . 
MRP2, MRP3 and MRP4 are localized predominantly at the syncytiotrophoblast 
brush border membrane [12, 13]. MRP1 is expressed in the syncytiotrophoblast and 
fetal capillary endothelium, with predominant staining in the fetal capillary 
endothelium [12, 14]. There is conflicting data on the syncytiotrophoblast localization 
of MRP1. While one study reports predominantly brush border membrane 
localization [12], the other reported only basal membrane localization [14]. Both of 
these studies utilized immunoblotting. MRP5 is located predominantly to the basal 
syncytiotrophoblast membrane, although some expression was also observed in the 
brush border membrane [15].  
 
Species as well as tissue differences exist with regards to the relative contribution of 
the efflux transporters responsible for the elimination of sulfates [3, 16, 17]. It is 
important to identify the transporters responsible for sulfate excretion in order to 
understand the role of the placenta in the elimination of sulfated metabolites in 
general, as well as to understand the potential for placental accumulation/fetal 
exposure of toxic sulfate metabolites.  
 
The objective of the present work was to determine the efflux transporters responsible 
for the elimination of sulfate conjugates out of trophoblast cells using the BeWo cell 
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line as a human trophoblast model. The mRNA of BCRP and several of the MRP 
isoforms are expressed in BeWo cells, and protein expression has been determined 
for BCRP, MRP1, MRP2 and MRP5 [13, 18-20]. Although there are differences 
between primary trophoblast cells and BeWo cells with respect to the expression and 
function of several efflux transporters [13, 18], the BeWo subclone used in this study 
forms a polarized monolayer of cells when grown on transwells, with the apical and 
basolateral membranes representing the maternal-facing and fetal-facing trophoblast 
membranes respectively [21]. This is of particular importance to our study as our 
objective is to begin describing the transporters responsible for the elimination of 
sulfate metabolites out of the placenta. A bidirectional transport study is a good way 
of determining if preferential excretion occurs across any one of the trophoblast 
membranes. We examined the fate of two common substances for sulfation pathways, 
4-nitrophenol and acetaminophen.  
 
4.2 Materials and methods 
4.2.1 BeWo cell culture 
The BeWo cell line (clone b30) was obtained from Dr. Alan Schwartz (Washington 
University, St. Louis, MO) and cultured as described previously [22]. Passages 29 
through 45 of the cells were used in this study. Briefly, cells were grown at 37ºC in an 
atmosphere of 5% CO2 and saturated relative humidity. They were maintained in 
Dulbecco’s Modified Eagles Medium (DMEM, Sigma, St. Louis, MO) containing 
10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), and 1% 
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each of 10,000 U/ml penicillin with 10,000 µg/mL streptomycin solution, 200 mM L-
glutamine solution, and 10 mM minimal essential medium nonessential amino acid 
solution (all three from Invitrogen, Carlsbad, CA). At 70-90% confluence, cells were 
detached with 0.5% trypsin and 0.2% ethylenediaminetetraacetic acid (EDTA, Sigma, 
St. Louis, MO) diluted in phosphate buffered saline (PBS) at a 1:10 ratio. Cells were 
then subcultured at a ratio of 1:10. 
 
4.2.2 Accumulation studies 
For accumulation studies cells were seeded onto poly-d-lysine (Sigma, St. Louis, 
MO) and fibronectin (Sigma, St. Louis, MO) coated plates at a cell density of 12,500 
cells/cm
2
 as per the protocol of Bode et al [22]. BeWo monolayers were used for the 
uptake studies once they reached 90-100% confluence (4-6 days). The cells were 
washed twice in warm (37ºC) HBSS (Sigma, St. Louis, MO) containing 25 mM 
glucose (HBSS-Glc). They were then allowed to equilibrate in HBSS-Glc at 37ºC on 
a shaker (~ 50 rpm) for 30 minutes. Cells were then incubated with pre-warmed 
(37ºC) HBSS-Glc solutions containing mitoxantrone in the presence of either known 
BCRP inhibitors, fumitremorgin C or chrysin, or 4-nitrophenyl sulfate (0.5-200 µM) 
or acetaminophen sulfate (0.5-200 µM, all were from Sigma, St. Louis, MO). For the 
time-dependent studies 20 nM [
3
H] mitoxantrone (4 Ci/mmol, Moravek Biochemicals 
Inc., Brea, CA) was used. For the others 10 µM unlabeled mitoxantrone (Sigma, St. 
Louis, MO) containing 20 nM [
3
H] mitoxantrone (final specific activity 0.02 
Ci/mmol) was used. Fumitremorgin C was used at 5 µM and chrysin at 100 µM. Cells 
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were incubated for 150 minutes with shaking at 50 rpm At the end of the 
accumulation period, the dosing solutions were aspirated off and the cells were 
washed thrice with ice-cold HBSS-Glc. Following this, the cells were lysed for 2 
hours at 37ºC with a lysing solution containing 0.5% Triton X-100 (Sigma, St. Louis, 
MO) in 0.2N NaOH. The cell lysates were analyzed by liquid scintillation counting 
and their protein content determined by the BCA assay kit (Pierce Chemical, 
Rockford, IL). Accumulation studies of 500nM BODIPY® FL prazosin (Invitrogen, 
Carlsbad, CA) was performed in a similar manner with the following exceptions: the 
dosing solutions were prepared in HBSS-Glc containing 2% BSA (Sigma, St. Louis, 
MO) and the lysing solution contained 2% Triton X-100. Fluorescence was detected 
using a Bio-Tek FL600 Microplate Fluorescence Reader (Bio-Tek Instruments, Inc., 
Winooski, VT), with excitation at 485 nm and emission at 535 nm.    
 
4.2.3 Bidirectional transport studies 
For the bidirectional transport studies BeWo cells were seeded onto 0.4 µM pore size 
Transwell
®
 plates (Costar Corporation, Acton, MA) at a density of 45,000 cells/cm
2
. 
Transwells were coated with human placental collagen (Sigma, St. Louis, MO)  prior 
to seeding as per the method of Bode et al [22]. All experiments were conducted 
between days 5-8. Stock solutions of 4-nitrophenol, 4-nitrophenyl sulfate, 
acetaminophen, acetaminophen sulfate, 3-methyl-4-nitrophenol and cimetidine (all 
from Sigma, St. Louis, MO) were prepared in HBSS, allowed to shake overnight, and 
filtered prior to use. 0.5 µM fluorescein (Sigma, St. Louis, MO) was prepared in 
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HBSS. Prior to the experiments HBSS and drug solutions were pre-warmed to 37
o
C. 
The volume of solutions added to the apical chamber was 0.5 mL while that added to 
the basolateral chamber was 1.5 mL. Cell monolayers were incubated in HBSS for 20 
minutes following which compound along with 0.5 µM fluorescein was added to 
either the apical or the basolateral chambers. The cells were then incubated at 37ºC 
with shaking (50 rpm). At 5, 10, 20, 30, and 45 minutes, 200 µL of the receiver 
chamber was withdrawn and replaced with fresh HBSS. The samples were then spun 
down at 2,500 RCF for 15 minutes and the supernatant analyzed by LC-MS/MS. The 
integrity of the monolayer was assessed by determining the permeability of 
fluorescein alone in separate monolayers. 
 
The studies examining the effect of inhibitors on the basolateral elimination of 4-
nitrophenyl sulfate were performed in a similar fashion. Monolayers were pre-
incubated with inhibitor for 30 minutes in both apical and basolateral chambers. 
Inhibitors used were 25 µM MK-571 (Biomol, Plymouth Meeting, PA), 0.2 µM 
leukotriene C4 (Biomol, Plymouth Meeting, PA), or 5 µM fumitremorgin C. The 
preincubation solution was then aspirated off and the cells were incubated with 50 
µM 4-nitrophenol solution containing inhibitors. Control cells contained vehicle 
instead of the inhibitors. The rest of the procedure was as outlined above except that 
during sampling of the receiver chamber, the volume withdrawn was replaced with 
HBSS containing inhibitor.  
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Samples from transport studies were analyzed by LC-MS/MS (LC coupled to Quattro 
Triple Quadrupole mass spectrometer). All separations were done on a Phenomenex 
Luna C18 column (2.0 x 50 mm, 5  µM pore size). The injection volume was 20 µL. 
4-nitrophenol (PNP), 4-nitrophenyl sulfate (PNPS) and the internal standard 3-
methyl-4-nitrophenol (MPNP) were separated using a mobile phase gradient at a flow 
rate of 0.3 mL/min. Solvent A was water containing 0.1% formic acid, while solvent 
B was acetonitrile containing 0.1% formic acid. The solvents were held at 95:5 A:B 
for 2 minutes, ramped to 30:70 A:B from 2 to 4.5 minutes, maintained at 30:70 A:B 
from 4.5 to 9.5 minutes, changed to 95:5 A:B from 9.5 to 10 minutes and then held at 
this composition until 15 minutes. They were detected in negative ion mode using 
multiple reaction monitoring: PNP (138 → 108), PNPS (217.95 → 138.05), and 
MPNP (152 → 122) (figure 4.2.1). To reduce exposure of the mass spectrometer to 
possible salts and cellular contaminants in the sample, the HPLC eluent was diverted 
to waste for the first 4 minutes.  
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Figure 4.2.1 Representative MS chromatograms of 4-nitrophenol (PNP), 4-
nitrophenyl sulfate (PNPS), and 3-methyl-4-nitrophenol (MPNP). The analytes 
were detected in negative ion mode using multiple reaction monitoring: PNP (138 → 
108), PNPS (217.95 → 138.05), and MPNP (152 → 122). 
 
Acetaminophen, acetaminophen sulfate (AS), and the internal standard cimetidine 
were separated using a mobile phase gradient at a flow rate of 0.3 mL/min. Solvent A 
was water containing 0.1% formic acid, while solvent B was acetonitrile containing 
0.1% formic acid. The solvents were held at 100:0 A:B for 1 minute, ramped to 50:50 
A:B from 1 to 2.5 minutes, maintained at 50:50 A:B from 2.5 to 4.5 minutes, changed 
to 100:0 A:B from 4.5 to 5.5 minutes, and then held at this composition for another 
3.5 minutes. AS and cimetidine were detected in negative ion mode: AS (230.1 → 
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149.8), cimetidine (251.2 → 156.9) as seen in figure 4.2.2. Acetaminophen and 
cimetidine were detected in positive ion mode: acetaminophen (152 → 110), 
cimetidine (253 → 117). The HPLC eluent was diverted to waste for the first 3 
minutes. 
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Figure 4.2.2 Representative MS chromatograms of acetaminophen sulfate (AS) 
and cimetidine. The analytes were detected in negative ion mode using multiple 
reaction monitoring: AS (230.1 → 149.8), and cimetidine (251.2 → 156.9). 
 
 Analytes were quantified from standard curves with the standards prepared in HBSS. 
Figures 4.2.3, 4.2.4, and 4.2.5 are representative calibration curves of 4-nitrophenol, 
4-nitrophenyl sulfate, and acetaminophen sulfate. Standards exhibited good linearity 
over a calibration range of 5-250 ng/mL (exact concentrations have been listed in the  
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Figure 4.2.3 Calibration curve of 4-nitrophenol. Linearity was observed in the 
range 3-280 ng/mL.  
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Figure 4.2.4 Calibration curve of 4-nitrophenyl sulfate. Linearity was observed in 
the range 3-260 ng/mL.  
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Figure 4.2.5 Calibration curve of acetaminophen sulfate. Linearity was observed 
in the range 1.3-270 ng/mL.  
 
figure legends). The lower limit of detection for acetaminophen sulfate was 1.4 
ng/mL. At the lowest concentrations, 4-nitrophenol and 4-nitrophenyl sulfate 
exhibited S/N ratios of 440 and 100 respectively.   
 
4.2.4 Efflux studies 
For efflux studies, cells were seeded onto poly-d-lysine and fibronectin coated plates 
at a cell density of 12,500 cells/cm
2
 as per the protocol of Bode et al [22]. Plates were 
used 6-9 days post-seeding. Cells were washed thrice in warm HBSS (37ºC) and pre-
incubated with HBSS containing inhibitor for 30 minutes. Inhibitors used were 5 µM 
and 25 µM MK-571; 10 and 100 µM indomethacin (Sigma, St. Louis, MO); 5 µM 
fumitremorgin C; 200 µM chrysin; and 0.1 µM and 0.2 µM leukotriene C4. The 
incubation medium was then aspirated away. The cells were freshly incubated with 1 
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µM 4-nitrophenol or 250 µM acetaminophen in the presence/absence of inhibitors for 
2 hours and 4 hours, respectively. The incubation medium was then collected, spun 
down at 2,500 RCF for 15 minutes, and analyzed for the sulfated metabolites by LC-
MS/MS. The analytical methods were the same as used in section 4.2.3. 
  
4.2.5 Determination of sulfotransferase enzyme activities 
BeWo cell lysate was prepared and sulfotransferase activities measured according to 
the procedure of Hu et al. [23] with slight modifications. BeWo cells at confluence 
were scraped up in PBS. The cells were centrifuged, PBS was aspirated away, and the 
cells were then suspended in 50 mM potassium phosphate buffer (pH 7.4) and 
homogenized on ice for 30 seconds with a Polytron homogenizer. The homogenate 
was spun down at 14,000 rpm for 15 minutes, the supernatant withdrawn and spun 
down at 14,000 rpm for 15 minutes again. The resultant supernatant was stored at -
80ºC for further use. Protein concentration was determined using a BCA assay kit 
(Pierce, Rockford, IL). Sulfotransferase activities were measured as follows: Cell 
lysate at a final concentration of 0.9 mg protein/mL was added to 100µM 3’-
phosphoadenosine-5’-phosphosulfate (PAPS, Sigma, St. Louis, MO) and 1 µM 4-
nitrophenol/250 µM acetaminophen in a total reaction volume of 100 µL. The 
mixture was incubated at 37ºC for 2 hours in the case of 4-nitrophenol and 4 hours in 
the case of acetaminophen. The reaction was stopped by the addition of 25 µL of 94% 
acetonitrile/6% glacial acetic acid containing the internal standards 3-methyl-4-
nitrophenol or cimetidine. The samples were then centrifuged at 14,000 rpm for 15 
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minutes and the supernatant analyzed by LC-MS/MS. The analytical methods were 
the same as used in section 4.2.3.     
 
4.2.6 Permeability calculations 
The following equation was used to calculate permeability in either the apical to 
basolateral direction (Papp,A  to B) or basolateral to apical direction (Papp,B to A) [24] : 
 
 
Papp = 
dt
dC
 x 
A
Vr  x Cd 
Where dC/dt is the change in concentration in the receiver compartment with respect 
to time, Vr is the volume of the receiver compartment, A is the growth surface area, 
and Cd is the initial concentration of the compound added to the donor compartment. 
The permeability directional ratio (PDR) was calculated as follows: 
 
PDR = Papp, B to A/ Papp, A  to B 
 
Metabolite excretion rates (Vmt) from the cell was calculated as reported before [25, 
26] . Metabolite excretion rates were obtained by monitoring the change of metabolite 
concentration (Cm) in the receiver chamber as a function of time. 
 
Vmt = 
dt
dCm x Vr 
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4.2.7 Statistical analysis 
Statistical significance was determined using One-way analysis of variance 
(ANOVA) followed by Dunnett’s post-comparison test (GraphPad Prism software) or 
the student’s t-test as deemed appropriate. A p-value of less than 0.05 was considered 
to be statistically significant.  
 
4.3 Results  
4.3.1 Effect of acetaminophen sulfate and 4-nitrophenyl sulfate on the 
accumulation of mitoxantrone and BODIPY® FL prazosin   
BCRP, MRP1 and MRP5 proteins are expressed in BeWo cells [18-20]. Some studies 
failed to detect MRP2 protein expression in BeWo cells while others have reported 
weak expression [18-20]. In BeWo cells, BCRP mRNA levels were reported to be 
much higher than those of MRP1 or MRP2 [27]. These studies did not examine the 
membrane localization of the transporters in BeWo cells. However, in 
syncytiotrophoblast BCRP and MRP2 are localized to the apical membrane, while 
MRP1 and MRP5 are localized to both membranes. BeWo cells consist primarily of 
cytotrophoblast-like cells [28]. Assuming similar transporter localization in 
syncytiotrophoblast and BeWo cells, the initial hypothesis was that BCRP would 
predominantly mediate sulfate metabolite elimination across the apical trophoblast 
membrane. To examine this hypothesis, the effect of acetaminophen sulfate and 4-
nitrophenyl sulfate on the accumulation of the BCRP substrates BODIPY® FL 
prazosin and [
3
H]-mitoxantrone was determined. If the sulfates altered accumulation 
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of the BCRP substrates, it would indicate an interaction of BCRP with the sulfates, 
and would imply a potential role of BCRP in sulfate elimination. 
 
BODIPY® FL prazosin and [
3
H]-mitoxantrone were used at concentrations that are 
typically used for BCRP [29, 30]. Accumulation of both mitoxantrone and 
BODIPY® FL prazosin reached steady state after the first hour of incubation (Figures 
4.3.1 and 4.3.2). The presence of the BCRP-specific inhibitor fumitremorgin C 
(FTC), on an average, increased the accumulation of BODIPY® FL prazosin by 1.5-2 
fold and that of mitoxantrone by 1.3-1.5 fold. The accumulation of both substrates in 
the presence/absence of FTC was on an average most significantly different at 150 
minutes. Hence an accumulation period of 150 minutes was utilized for all 
subsequent experiments.  
 
4-nitrophenyl sulfate (0.5-200 µM) did not alter the accumulation of mitoxantrone 
(Figure 4.3.3). In the same concentration range, 4-nitrophenyl sulfate did not affect 
the accumulation of BODIPY® FL prazosin either except at 200 µM where it 
produced a statistically significant increase in accumulation suggesting it to be a 
potential BCRP inhibitor at this concentration (Figure 4.3.4). The increase in 
accumulation (1.5-1.8 fold) was comparable to that produced by fumitremorgin C 
(1.5-2 fold). Acetaminophen sulfate (0.5-200 µM) did not affect the accumulation of 
either mitoxantrone or BODIPY® FL prazosin (Figures 4.3.5 and 4.3.6) suggesting 
no interaction with BCRP.  
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The structure of the membrane-bound ATP-binding cassette (ABC) family of 
transporters reveals that they consist of trans-membrane domains and cytosolic 
domains. The substrate-binding sites of these transporters are usually located on the 
trans-membrane domains and substrates gain access to the binding site from the 
membrane-cytosolic interface [31]. It can be contended that in these experiments the 
charged sulfates would not be able to permeate the cells and thus would not gain 
access to the transporter-binding site. BeWo cells, however, have been reported to 
take up organic anions via temperature-sensitive mechanisms indicating carrier-
mediated transport [27]. Although 4-nitrophenyl sulfate or acetaminophen sulfate 
uptake has not been demonstrated in BeWo cells, both sulfates are taken up by 
carrier-mediated processes in isolated hepatocytes [32, 33]. BeWo cells produce 4-
nitrophenyl sulfate upon incubation with 4-nitrophenol (Figure 4.3.10). To assess if 
intracellularly-generated 4-nitrophenyl sulfate affected the accumulation of 
mitoxantrone in a different manner, BeWo cell monolayers were incubated with 4-
nitrophenol (0.5-200 µM). We found that under these conditions the accumulation of 
mitoxantrone decreased by 10-30%. As this was not dose dependent, it indicated that 
intracellularly generated 4-nitrophenyl sulfate did not interact with BCRP and implied 
a minor role of BCRP in sulfate elimination.  
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Figure 4.3.1 Time-dependent accumulation of mitoxantrone (MTX) in BeWo 
cells. Accumulation of 20 nM [
3
H]-mitoxantrone (4 Ci/mmol) was measured at 37ºC 
as a function of time, in the absence or presence of the BCRP-specific inhibitor 
fumitremorgin C (FTC). Each experiment was repeated in triplicate with each point 
and bar in an individual experiment representing the mean ± S.E.M. of triplicate 
measurements. * indicates p < 0.05. 
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Figure 4.3.2 Time-dependent accumulation of BODIPY® FL prazosin in BeWo 
cells. Accumulation of 500 nM BODIPY® FL prazosin was measured at 37ºC as a 
function of time, in the absence or presence of the BCRP-specific inhibitor 
fumitremorgin C (FTC). Each experiment was repeated in triplicate with each point 
and bar in an individual experiment representing the mean ± S.E.M. of triplicate 
measurements. * indicates p < 0.05. 
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Figure 4.3.3 Effect of 4-nitrophenyl sulfate (PNPS) on the accumulation of 
mitoxantrone (MTX). Accumulation of 10 µM mitoxantrone (specific activity 0.02 
Ci/mmol) was measured in the presence of 4-nitrophenyl sulfate (0.5-200 µM) at 
37ºC for 150 minutes. Known BCRP inhibitors fumitremorgin C (FTC) and chrysin, 
at 5 µM and 100 µM respectively, served as the positive controls. Control cells 
contained mitoxantrone alone. Each data point in an individual experiment represents 
quadruplicate measurements. Data has been plotted as mean ± S.E.M. * indicates p < 
0.05. 
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Figure 4.3.4 Effect of 4-nitrophenyl sulfate (PNPS) on the accumulation of 
BODIPY® FL prazosin. Accumulation of 500 nM BODIPY® FL prazosin was 
measured in the presence of 4-nitrophenyl sulfate (0.5-200 µM) at 37ºC for 150 
minutes. The BCRP inhibitor fumitremorgin C (FTC) at 5 µM served as the positive 
control. Control cells contained BODIPY® FL prazosin alone. Each data point in an 
individual experiment represents quadruplicate measurements. Data has been plotted 
as mean ± S.E.M. * indicates p < 0.05.  
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Figure 4.3.5 Effect of acetaminophen sulfate (AS) on the accumulation of 
mitoxantrone (MTX) in BeWo cell monolayers. Accumulation of 10 µM 
mitoxantrone (specific activity 0.02 Ci/mmol) was measured in the presence of 
acetaminophen sulfate (0.5-200 µM) at 37ºC for 150 minutes. Known BCRP 
inhibitors fumitremorgin C (FTC) and chrysin, at 5 µM and 100 µM respectively, 
served as the positive controls. Control cells contained mitoxantrone alone. Each data 
point in an individual experiment represents quadruplicate measurements. Data has 
been plotted as mean ± S.E.M. * indicates p < 0.05.  
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Fig. 4.6 Effect of acetaminophen sulfate (AS) on the accumulation of BODIPY® 
FL prazosin in BeWo cells. Accumulation of 500 nM BODIPY® FL prazosin was 
measured in the presence of acetaminophen sulfate (0.5-200 µM) at 37ºC for 150 
minutes. Known BCRP inhibitors, fumitremorgin C (FTC) and chrysin, at 5 µM and 
100 µM respectively, served as the positive controls. Control cells contained 
BODIPY® FL prazosin alone. Each data point in an individual experiment represents 
quadruplicate measurements. Data has been plotted as mean ± S.E.M. * indicates p < 
0.05. 
 
4.3.2 Transport of 4-nitrophenyl sulfate 
Substrates of cellular efflux pumps exhibit asymmetrical apparent permeability 
coefficients in the apical to basolateral, and basolateral to apical directions. For e.g. a 
substance exhibiting a PDR of 2 or greater can be considered to be a substrate of an 
apically-located efflux transporter. The permeability of 0.5, 1 or 5 µM 4-nitrophenyl 
sulfate was determined. There was no change in the apparent permeability 
coefficients of 4-nitrophenyl sulfate with change in concentration and the PDR in all 
* 
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cases was approximately 0.75-1 (Figure 4.3.7). This was not due to 4-nitrophenyl 
sulfate affecting BeWo monolayer integrity because Papp, A-B and Papp, B-A of the 
paracellular marker fluorescein in the presence of 4-nitrophenyl sulfate were similar  
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Figure 4.3.7 Bidirectional transport of 4-nitrophenyl sulfate in BeWo cells. The 
apparent permeability coefficient (Papp) of 4-nitrophenyl sulfate was determined by 
incubating BeWo monolayers with 4-nitrophenyl sulfate (0.5, 1, and 5 µM) at 37ºC 
for a total period of 45 minutes. Papp was determined in the apical to basolateral (A-
B), as well as, basolateral to apical (B-A) directions. Each data point in an individual 
experiment represents triplicate measurements. Data has been plotted as mean ± S.D. 
 
to the values obtained when fluorescein was run alone (data not shown). The PDR ~ 1  
indicated passive diffusion to be the main process involved in the transport of 4-
nitrophenyl sulfate. Under the conditions utilized, BeWo cells were somewhat leakier 
paracellularly compared to other epithelial cell monolayers. Papp, A-B of the 
paracellular permeability marker Lucifer yellow in the apical to basolateral direction 
was determined to be ~ 10 x 10
-6
 cm/sec. This is more than 10-fold higher than what 
4-nitrophenyl sulfate (µM) 
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is considered acceptable for Caco-2 monolayers. It is possible that under such 
conditions the contributions of passive transport were much higher than that of active 
transport, and this generated an efflux ratio ~ 1. Bidirectional transport of 
acetaminophen sulfate was not determined for the same reason.   
 
4.3.3 Excretion of 4-nitrophenyl sulfate upon 4-nitrophenol incubation 
BeWo monolayers were incubated with 4-nitrophenol in either the apical or 
basolateral chambers. The appearance of 4-nitrophenol and 4-nitrophenyl sulfate, 
were monitored in the receiver chambers.  At all concentrations (0.5-50 µM), the 
PDR of 4-nitrophenol was between 0.7-1 (table 4.1). Neither Papp, A-B, nor Papp, B-A, of 
4-nitrophenol underwent saturation with increasing concentrations indicating passive 
diffusion to be the main route of elimination across both apical as well as basolateral 
membranes (Table 4.1).  
 
4-nitrophenyl sulfate appeared in both donor and receiver chambers. The amount of 
sulfate appearing in the receiver chamber increased linearly with time for both 
basolateral as well as apical elimination (data not shown). The excretion rates of 4-
nitrophenyl sulfate (Figure 4.3.8 and table 4.1) across the apical and basolateral 
membranes did not change as a function of 4-nitrophenol concentration indicating 
that in the utilized concentration range either metabolism or transport had already 
been saturated. At all concentrations the excretion rates across both membranes were 
almost equal. This suggested that the transporter(s) on both membranes eliminate 4-
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nitrophenyl sulfate with equal efficiency. Analytical issues prevented examination of 
apical or basolateral elimination of acetaminophen sulfate under similar conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.8 Excretion of 4-nitrophenyl sulfate as a function of 4-nitrophenol 
dosing concentration. BeWo cell monolayers were grown on transwells. The apical 
or basolateral chambers were treated with 4-nitrophenol at 37ºC for 45 minutes. The 
excretion rate of 4-nitrophenyl sulfate across the basolateral (black bars) and apical 
(gray bars) membranes was estimated after apical or basolateral exposures, 
respectively, of 4-nitrophenol. Each data point in an individual experiment represents 
triplicate measurements. Data has been plotted as mean ± S.D. A-B denotes apical to 
basolateral transport while B-A denotes basolateral to apical transport.    
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Table 4.1 Apparent permeability of 4-nitrophenol and excretion rates of 4-
nitrophenyl sulfate. BeWo monolayers grown on transwells were treated with 4-
nitrophenol in either the apical or basolateral chambers, at 37ºC for 45 minutes. The 
receiver chamber was periodically sampled for 4-nitrophenol and 4-itrophenylsulfate 
to determine the apparent permeability coefficient (Papp) of 4-nitrophenol, and the 
excretion rates of 4-nitrophenyl sulfate. Data has been plotted as mean ± S.D (n=3). 
A-B denotes apical to basolateral transport while B-A denotes basolateral to apical 
transport.   
 
 
4-nitrophenol 4-nitrophenyl sulfate 
Papp x 10
6
 
(cm/sec) 
Excretion rate  (pmol/min) 
4-nitrophenol 
(µM) 
A-B B-A 
PDR 
A-B B-A 
0.5 34.5±5.07 24.1±2.10 0.70±0.12 1.48±0.13 1.13±0.14 
1 33.4±3.19 34.0±2.44 1.02±0.12 1.14±0.24 1.88±0.12 
5 46.0±5.74 37.1±4.99 0.81±0.15 0.86±0.16 0.93±0.08 
25 33.4±3.19 34.0±2.44 1.02±0.12 0.92±0.11 1.23±0.11 
50 21.9±5.25 20.5±1.84 0.94±0.24 0.73±0.19 0.55±0.06 
 
 
4.3.4 Efflux of the sulfate metabolites across the apical membrane 
To determine efflux across the apical membrane, cells were plated onto 12-well 
uptake plates and at confluence were incubated with 4-nitrophenol (1 µM, 10 µM, or 
25 µM) or acetaminophen (10 µM, 50 µM, or 250 µM). The transport medium was 
analyzed for 4-nitrophenyl sulfate or acetaminophen sulfate. At all concentrations of 
4-nitrophenol, the concentrations of 4-nitrophenyl sulfate determined in the transport 
medium increased linearly with time up to an incubation period of 4 hours (data not 
shown). Similarly, at all concentrations of acetaminophen, acetaminophen sulfate in 
the transport medium increased linearly as a function of time (Figure 4.3.9). An 
 126 
incubation time of 2 hours was selected for future experiments with 4-nitrophenol (1 
µM). An incubation period of 4 hours was selected for acetaminophen (250 µM) for 
improved detection (this has been discussed in section 4.4).  
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Figure 4.3.9 Appearance of intracellularly generated acetaminophen sulfate in 
the incubation medium as a function of time. BeWo cell monolayers grown on 12-
well plates were incubated with 10, 50, or 250 µM acetaminophen at 37ºC for 1, 2, 3, 
or 4 hours. Following this, the incubation medium was withdrawn and analyzed for 
acetaminophen sulfate. Each data point in an individual experiment represents 
triplicate measurements. Data has been plotted as mean ± S.E.M. * indicates p < 0.05. 
 
Efflux of acetaminophen sulfate across the apical membrane underwent a dose-
dependent decrease in the presence of the MRP inhibitors MK-571 and indomethacin 
(Figure 4.3.10). Another MRP inhibitor leukotriene C4 (LTC4) did not produce any 
effect. 5 µM of the BCRP-specific inhibitor FTC also produced a significant decrease 
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in efflux; the amount of acetaminophen sulfate effluxed being ~77% of vehicle-
treated controls. Much lesser amounts were eliminated at the highest concentrations 
of MK-571 (~26%) and indomethacin (~58%). Maximum inhibition was produced by 
200 µM chrysin (~8%). Similar results were obtained with the apical efflux of 4-
nitrophenyl sulfate (Figure 4.3.11). The percentage of 4-nitrophenyl sulfate detected 
in the transport medium was ~20% in the presence of 25 µM MK-571, ~70% in the 
presence of 100 µM indomethacin, ~85% in the presence of 5 µM FTC and 
undetectable in the presence of chrysin. Leukotriene C4 did not produce any effect. 
All the above values denote the percentage of the sulfate metabolite detected in the 
transport medium in the presence of inhibitors with respect to the vehicle-treated 
controls.  
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Figure 4.3.10 Effect of transporter inhibitors on the efflux of acetaminophen 
sulfate from the apical membrane of BeWo cells. BeWo monolayers grown on 12-
well plates were incubated with 250 µM acetaminophen at 37ºC for 4 hours, in the 
presence of MRP inhibitors (MK-571, indomethacin, and leukotriene C4) or BCRP 
inhibitors (fumitremorgin C and chrysin). Control cells contained the vehicle alone. 
At the end of 4 hours, the incubation medium was analyzed for acetaminophen 
sulfate. Each data point in an individual experiment represents triplicate 
measurements. Data has been plotted as mean ± S.E.M. * indicates p < 0.05 
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Figure 4.3.11 Effect of transporter inhibitors on the efflux of 4-nitrophenyl 
sulfate from the apical membrane of BeWo cells. BeWo monolayers grown on 12-
well plates were incubated with 1 µM 4-nitrophenol at 37ºC for 2 hours, in the 
presence of MRP inhibitors (MK-571, indomethacin, and leukotriene C4) or BCRP 
inhibitors (fumitremorgin C and chrysin). At the end of 2 hours, the incubation 
medium was analyzed for 4-nitrophenyl sulfate. Each data point in an individual 
experiment represents triplicate measurements. Data has been plotted as mean ± 
S.E.M. * indicates p < 0.05. 
 
4.3.5 Inhibition of 4-nitrophenyl sulfate elimination across the basolateral 
membrane 
To investigate the transporters involved in the elimination of 4-nitrophenyl sulfate 
across the basolateral membrane, the apical to basolateral transport of 50 µM 4-
nitrophenol was determined in the presence of various inhibitors. Both MRP 
inhibitors MK-571 (25 µM) and LTC4 (0.2 µM) inhibited the excretion rate of 4-
nitrophenyl sulfate across the basolateral membrane by approximately 50% (Figure 
* 
* 
* 
* 
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4.3.12). 5 µM FTC decreased the excretion rate of 4-nitrophenyl sulfate to the same 
extent as MK-571 and leukotriene C4, but this was not statistically significant.   
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Figure 4.3.12 Effect of transporter inhibitors on the elimination of 4-nitrophenyl 
sulfate across the basolateral membrane of BeWo cells. The apical chambers of 
BeWo monolayers grown on transwells were incubated with 50 µM 4-nitrophenol at 
37ºC for 45 minutes, in the absence and presence of the different inhibitors. MK-571 
and leukotriene C4 are MRP inhibitors whereas fumitremorgin C is a BCRP inhibitor. 
The excretion rate of 4-nitrophenyl sulfate across the basolateral membrane was 
obtained by determining the concentrations of 4-nitrophenyl sulfate in the basolateral 
chamber as a function of time. Each data point in an individual experiment represents 
triplicate measurements. Data has been plotted as mean ± S.E.M. * indicates p < 0.05. 
 
4.3.6 Effect of inhibitors on sulfate metabolite formation in BeWo cell lysate 
To determine if the inhibitors used in the preceding section selectively affected 
transport, their effect on sulfate conjugation was determined. Only inhibitor 
* 
* 
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concentrations that had produced a statistically significant change in the efflux or 
transport studies (sections 4.3.4 and 4.3.5) were used. For 1 µM 4-nitrophenol, in the 
presence of 5 µM MK-571, 25 µM MK-571, 100 µM indomethacin, 200 µM chrysin,  
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Figure 4.3.13 Effect of inhibitors on the formation of 4-nitrophenyl sulfate in 
BeWo cells. BeWo cytosolic homogenate was incubated with 1µM or 50µM 4-
nitrophenol and 100µM 3’-phosphoadenosine-5’-phosphosulfate (PAPS) for 2 hours 
at 37ºC in the absence and presence of different efflux transporter inhibitors. The 
reaction mixture was then analyzed for 4-nitrophenyl sulfate. 4-nitrophenyl sulfate 
formed in the presence of inhibitors was normalized to the amount produced in the 
vehicle-treated controls. Solid and open bars indicate that lysate was incubated with 
1µM and 50µM 4-nitrophenol respectively. Each data point in an individual 
experiment represents triplicate measurements and data has been plotted as mean ± 
S.E.M. * indicates p < 0.05. 
 
and 5µM FTC, the amount of  4-nitrophenyl sulfate produced was 36%, 11%, 1%, 
74%, and 131% of the vehicle-treated controls respectively (Figure 4.3.13). The 
changes in all these cases were statistically significant. For 50 µM 4-nitrophenol, in 
* 
* 
* 
* 
* 
* 
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the presence of 25 µM MK-571, 54% of 4-nitrophenyl sulfate was produced. 
Leukotriene C4 did not produce any change in the amount of 4-nitrophenyl sulfate 
produced. In contrast, none of the inhibitors changed the formation of acetaminophen 
sulfate (Figure 4.3.14).     
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.14 Effect of inhibitors on the formation of acetaminophen sulfate in 
BeWo cells. BeWo cytosolic homogenate was incubated with 250 µM acetaminophen 
and 100 µM 3’-phosphoadenosine-5’-phosphosulfate (PAPS) for 4 hours at 37ºC in 
the absence and presence of different efflux transporter inhibitors. The reaction 
mixture was then analyzed for acetaminophen sulfate. Acetaminophen sulfate formed 
in the presence of inhibitors was normalized to the amount produced in the vehicle-
treated controls. Data has been plotted as mean ± S.E.M. * indicates p < 0.05. 
 
4.4 Discussions and conclusions 
Low oral bioavailability of several drugs has been attributed to extensive intestinal 
metabolism and excretion of the metabolites back into the intestinal lumen. The 
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multidrug resistance-associated proteins (MRPs) and the organic anion transporters 
(OATs) have been reported to be the major transporters responsible for the 
elimination of sulfate metabolites out of Caco-2 cells. Excretion of the sulfate and 
glucuronide conjugates of several isoflavones as well as some pharmaceutical drugs 
were all inhibited to some extent at least by MRP inhibitors MK-571, leukotriene C4, 
and the OAT inhibitor estrone sulfate in Caco-2 [23, 25, 26]. Interestingly none of 
these earlier studies examined the involvement of BCRP in the efflux of the sulfate 
and glucuronide conjugates. In a more recent study, BCRP, but not MRP, 
significantly decreased apical  sulfate metabolite efflux in Caco-2 [34]. This suggests 
that one of the roles of BCRP in the intestine may be the elimination of sulfate 
conjugates. This agrees well with reports of BCRP predominantly mediating the 
biliary excretion of xenobiotic sulfate conjugates in mice [3]. There are tissue-specific 
and species-specific differences with respect to the relative contributions of the 
transporters. In contrast to mice, in rats MRP2 primarily mediated the biliary efflux of 
xenobiotic sulfate conjugates [16]. While BCRP was a major contributor in the biliary 
efflux of troglitazone sulfate in mice, it only played a minor role in the intestinal 
mucosal efflux of this sulfate [17]. This differential effect makes it more important to 
determine which transporters are responsible for conjugate efflux in placenta.  
 
In the accumulation studies acetaminophen sulfate did not affect the accumulation of 
either BODIPY® FL prazosin or mitoxantrone suggesting that acetaminophen sulfate 
does not interact with BCRP. 4-nitrophenyl sulfate did not alter the accumulation of 
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mitoxantrone or BODIPY® FL prazosin, except at 200 µM where it increased 
BODIPY® FL prazosin accumulation. Hence, 4-nitrophenyl sulfate can be concluded 
to be an inhibitor of BCRP only at high concentrations. Although not as effective, this 
is in agreement with the study of Suzuki et al. [35] who showed that 4-nitrophenyl 
sulfate inhibited BCRP-mediated transport of estrone sulfate in membrane vesicles 
obtained from mouse lymphoma P388 cells (IC50 = 53 µM). The extent to which 4-
nitrophenyl sulfate or acetaminophen sulfate increased accumulation was compared 
with the effects produced by FTC and chrysin. While FTC is a BCRP-specific 
inhibitor [36, 37], chrysin inhibits BCRP, MRP1, and P-gp [38]. In all experiments 
the increase in accumulation produced in the presence of chrysin was much higher 
than that produced by FTC. A possible reason for this could be that BODIPY® FL 
prazosin and mitoxantrone are being effluxed out by transporters in addition to 
BCRP. Though BODIPY® FL prazosin and mitoxantrone were used at 
concentrations typically used to test for BCRP, they are not BCRP-specific substrates. 
BODIPY® FL prazosin is a substrate of P-gp also [39]; while mitoxantrone is known 
to be a substrate of MRP1 and P-gp as well [40]. Therefore, we can conclude that in 
the tested concentration range, acetaminophen sulfate and 4-nitrophenyl sulfate do 
not interact with BCRP, P-gp, or MRP1. This suggested a minor role of BCRP and 
MRP1 in apical sulfate elimination. 
 
Bidirectional transport studies of 4-nitrophenyl sulfate did not reveal if it was 
preferentially eliminated across the apical or basolateral membranes. To avoid any 
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contributions of paracellular permeability the cells were incubated with 4-nitrophenol 
and the appearance of intracellularly generated 4-nitrophenyl sulfate was monitored. 
Further, the excretion rates of 4-nitrophenyl sulfate across either membrane were 
about the same at all concentrations. These findings indicated that the transporter(s) 
on both membranes efflux out 4-nitrophenyl sulfate at similar rates. In our hands 
BeWo monolayer integrity was compromised (i.e. the monolayers lifted off the 
transwell membranes) at incubation times longer than 60 minutes. Acetaminophen 
sulfate was not detectable in the transport medium at 60 minutes or less, and hence 
we were unable to determine the excretion pattern of acetaminophen sulfate across 
the apical and basolateral membranes. 
 
Efflux assays conducted with BeWo monolayers grown on multiwell plates, allowed 
for longer incubation times. Upon incubation with 4-nitrophenol or acetaminophen, 
the amounts of 4-nitrophenyl sulfate and acetaminophen sulfate detected in the 
transport medium increased linearly as a function of time. Hence, longer incubation 
times markedly improved the detection of acetaminophen sulfate. Since we monitored 
the transport medium for the sulfate metabolite, this gave us information on sulfate 
elimination from the apical trophoblast membrane. Results from the efflux assay 
indicated that one or more of the MRP proteins are primarily responsible for apical 
elimination of 4-nitrophenyl sulfate and acetaminophen sulfate with a lesser 
contribution from BCRP.  The MRP inhibitors utilized were not specific to a 
particular isoform and all the MRP isoforms expressed in BeWo cells (i.e., MRP 1, 2, 
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and 5), are expressed on the apical syncytiotrophoblast membrane to some extent at 
least [12, 13, 15]. Further, as studies have reported that MRP2 is either weakly 
expressed or not expressed in BeWo cells [18-20], it would be reasonable to 
hypothesize that MRP1 or MRP5 primarily mediate the apical elimination of 4-
nitrophenyl sulfate and acetaminophen sulfate. However, the involvement of any 
MRP isoform in the excretion of 4-nitrophenyl sulfate is complicated by the fact that 
both MK-571 and indomethacin decreased the formation of 4-nitrophenyl sulfate as 
well. 100 µM indomethacin inhibited metabolism and apical efflux to approximately 
the same extent. In the presence of 5 µM and 25 µM MK-571 respectively, only 36% 
and 11% of PNPS was formed with respect to the vehicle-treated controls, while the 
amount effluxed were 47% and 19% of the controls respectively. Thus with the 
inhibitors used, no conclusion could be reached about the role of MRP isoforms in the 
apical efflux of 4-nitrophenyl sulfate.  
 
The excretion of 4-nitrophenyl sulfate across the basolateral membrane was also 
significantly decreased in the presence of both MRP inhibitors MK-571 and 
leukotriene C4. In contrast to MK-571, leukotriene C4 affected only transport and not 
metabolism. Since out of the MRP isoforms detected in the basolateral 
syncytiotrophoblast membrane, MRP1 and MRP5 protein are expressed in BeWo 
cells, it would be reasonable to propose that either MRP1 or MRP5 mediate 4-
nitrophenyl sulfate excretion across the basolateral trophoblast membrane. Although 
FTC did not produce a statistically significant change in 4-nitrophenyl sulfate 
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elimination across the basolateral membrane, it reduced the excretion rate to almost 
the same extent as the MRP inhibitors. BCRP is localized to syncytiotrophoblast 
apical membrane with faint signals observed in basal membrane fractions [5, 11]. It is 
likely that BCRP inhibition drives 4-nitrophenyl sulfate excretion across a basolateral 
membrane transporter as has been reported with hesperitin sulfate elimination in 
Caco-2 [34].  
 
In several cases MK-571 at similar concentrations (as used in this study) or higher has 
been shown to inhibit sulfate efflux [23, 25, 41, 42]. In many of these cases the effect 
of the inhibitor on metabolism was not determined. While it has been shown that 
MK-571 did not affect apigenin sulfation up to a concentration of 100 µM, in this 
study the metabolism experiment was performed for 30 minutes whereas the intact 
cell efflux experiments were performed for 2 hours [23]. Our work shows for the first 
time that MK-571 affected formation and efflux of 4-nitrophenyl sulfate to almost the 
same extents. This underscores the importance of performing metabolic studies along 
with transport studies when determining the effect of inhibitors on metabolite efflux. 
 
In mice BCRP plays a major role in the biliary efflux of acetaminophen sulfate with a 
minor contribution from MRP2 [3]. Sinusoidal elimination of acetaminophen sulfate 
in mice is mediated by MRP3 and MRP4 [43]. In rat biliary excretion is mediated 
primarily by MRP2 with a small contribution from BCRP [3, 16]. Our study indicates 
a major contribution of MRP1/MRP5 in the apical efflux of acetaminophen sulfate 
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with a minor contribution from BCRP. Compared to acetaminophen sulfate, much 
less is known about which transporters are responsible for 4-nitrophenyl sulfate efflux 
in other tissues or even species. In rat liver 4-nitrophenyl sulfate undergoes biliary as 
well as sinusoidal excretion but the transporters responsible for it’s elimination have 
not been determined [44]. MRP3 and MRP4 on the hepatic basolateral membrane, 
and MRP2 and BCRP on the hepatic canalicular membrane, play major roles in the 
elimination of sulfate metabolites [6]. Our data indicates that like acetaminophen 
sulfate, a portion of the apical efflux of 4-nitrophenyl sulfate is mediated by BCRP 
while its basolateral excretion is mediated by either MRP1 or MRP5.  
 
In conclusion, we can say that BCRP is responsible for a small portion of the efflux 
of 4-nitrophenyl sulfate from the apical membrane of BeWo cells, while either MRP1 
or MRP5 mediate its basolateral elimination. Apical elimination of acetaminophen 
sulfate is mediated most likely, primarily by MRP1/ MRP5 with a minor contribution 
by BCRP. Our study suggests that another role of placental efflux transporters is 
elimination of xenobiotic sulfate conjugates. None of the inhibitors used in this study 
completely inhibited the efflux of either acetaminophen sulfate or 4-nitrophenyl 
sulfate. This suggests the involvement of other transporters such as the organic anion 
transporters (OATs) or the organic anion transporting polypeptides (OATPs). OAT 
isoforms partly mediate the intestinal efflux of sulfates of xenobiotics such as 
raloxifene and apigenin [23, 25]. Similarly several OATP isoforms transport  estrone 
sulfate and dehydroepiandrosterone sulfate [45]. In placenta OATP-E/4A1 and 
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OATP-B/2B1 are localized on apical and basolateral trophoblast membranes 
respectively, while OAT4 is localized on the basolateral trophoblast membrane [19, 
46]. A physiological function of OAT4 in the placenta is the uptake of 
sulfoconjugated steroids from the fetus for estrogen synthesis in the 
syncytiotrophoblast [46], while both OAT4 and OATP2B1 mediate the uptake of 
sulfated estrogens from the fetal circulation [46]. Future studies should examine if 
additional roles of placental organic anion transporters and organic anion transporting 
polypeptides include sulfate elimination out of the placenta. Further, BeWo cells do 
not express MRP3 or MRP4, which may also contribute to sulfate elimination in the 
placenta.  
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Chapter 5: Summary and Future Directions 
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5.1 Research summary  
Placental metabolism and transport have the potential of altering fetal exposure to 
drugs or natural substances in the maternal circulation. Sulfation of drugs has been 
detected in the placenta and several sulfotransferase enzymes have been identified in 
the syncytiotrophoblast layer. Among the efflux transporters known to transport 
sulfate conjugates, the breast cancer resistance protein (BCRP) and the multidrug-
resistance associated proteins 1, 2, 3 and 4 are located on the brush border (maternal-
facing) syncytiotrophoblast membrane, whereas MRP1 and MRP5 are located on the 
basal (fetal-facing) syncytiotrophoblast membrane. Not much is known though about 
the induction/inhibition of placental sulfotransferase enzymes, or if one of the 
functions of placental efflux transporters could be the elimination of sulfate 
metabolites. This work has addressed some of these questions.  
 
In chapter 2 we established that the phenolic sulfotransferase isoforms, SULT1A1 
and SULT1A3, are functional in BeWo cells and cytotrophoblast cells, while 
SULT1E1 and SULT2A1 are not functional in BeWo cells. The overall expression 
profile is in agreement with what has been reported before by Stanley et al., i.e., in 
placental fractions rich in syncytiotrophoblasts SULT1A1 and SULT1A3 activities 
were much higher than that of SULT1E1 [1]. Stanley et al. also reported high 
SULT2A1 activity in these fractions which is in contrast to our conclusion of 
SULT2A1 protein not being expressed in trophoblast [1]. A possible reason for the 
observed difference could be overlapping substrate specificity of different isoforms. 
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Enzyme activity assays as well as mRNA expression indicated that SULT1A1 was 
upregulated in BeWo cells whereas SULT1A3 was equivalently expressed in BeWo 
cells and the primary cytotrophoblast cells.  
 
Chapter 3 examined the effect of bisphenol A on SULT1A1 activity upon acute and 
chronic exposure. Bisphenol A was an acute inhibitor of SULT1A1 at concentrations 
much higher than that detected in random human serum samples. Chronic bisphenol 
A exposure resulted in inhibition of SULT1A1 activity. A U-shaped non-monotonic 
dose response curve was observed. Maximum inhibition (i.e., activity was reduced to 
60-70% of the activity observed in untreated cells) was observed at intermediate 
concentrations and the inhibition was at relevant concentrations. The nature of 
SULT1A1 inhibition indicated at least two mechanisms of regulation – one causing 
inhibition and the other induction of SULT1A1. The estrogen receptor (ER) β 
inhibitor ICI182780 did not restore SULT1A1 activities to control levels suggesting 
that the inhibitory effect of bisphenol A on SULT1A1 activity was not mediated via 
ERβ.  
 
Chapter 4 examined the mechanisms of elimination of the sulfate metabolites of two 
common SULT1A1 substrates, 4-nitrophenol and acetaminophen. BCRP mediated a 
minor portion of the elimination of 4-nitrophenylsulfate across the apical membrane, 
while either MRP1 or MRP5 mediated almost half of its excretion across the 
basolateral membrane. No conclusion was reached about the involvement of 
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MRP1/MRP2/ MRP5 in the apical elimination of 4-nitrophenylsulfate as the utilized 
MRP inhibitors affected the formation of 4-nitrophenylsulfate to almost the same 
extent that they affected its efflux. The inhibitors, however, did not affect the 
formation of acetaminophen sulfate leading to the conclusion that MRP1/MRP2/ 
MRP5 are responsible for the major portion of the apical elimination of 
acetaminophen sulfate with a minor contribution from BCRP.  
 
5.2 Overall conclusions 
This work shows that the BeWo cell line can be used successfully to examine the 
roles of SULT1A1 and SULT1A3 in placental metabolism. Bisphenol A inhibited 
SULT1A1 activity upon chronic exposure. The maximal inhibition was ~ 30%. As 
the effect is moderate and sulfation is a co-factor limited but not an enzyme-limited 
reaction, it would be interesting to observe if this produces any changes in in vivo 
situations with respect to fetal exposure. This work also shows that another placental 
function of placental efflux transporters is elimination of sulfate metabolites.  
 
Compared to other tissues, the placenta expresses high quantities of the steroid 
sulfatase enzyme (STS) whose physiological function in the placenta is the 
deconjugation of dehydroepiandrosterone sulfate (DHEAS) and 16-hydroxyl DHEAS 
taken up from the fetus for the de novo synthesis of estrogen in the 
syncytiotrophoblast [2]. It was proposed that OATP2B1 on the basolateral membrane 
and BCRP on the apical membrane function together to eliminate 
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dehydroepiandrosterone sulfate taken up from the fetal circulation [3]. In a 
subsequent study, it was mentioned that the high sulfatase concentrations in the 
syncytiotrophoblast makes this dual transport system an unlikely in vivo process [2]. 
The same reasoning can be extended against the role of trophoblast efflux transporters 
in the elimination of sulfate metabolites. However, compared to physiological 
substrates such as estrone sulfate and dehydroepiandrosterone sulfate, the steroid 
sulfatase enzyme exhibits a lower affinity for small molecules such as 4-
nitrophenylsulfate (Km = 400 µM for arylsulfatase C) [4], whereas SULT1A1 sulfates 
small molecules such as 4-nitrophenol at much lower concentrations (i.e., reported 
Km values of SULT1A1 for 4-nitrophenol ~ 1 µM) [5, 6]. The differential affinity 
indicates that in spite of the high expression of steroid sulfatase in the placenta, it is 
quite possible that the sulfotransferase enzymes and the efflux transporters might act 
in concert to reduce fetal exposure to sulfate metabolites.  
  
5.3 Future directions 
The BeWo cell line expresses several enzymes and transporters that are functional in 
the whole placenta and this makes it a useful model to predict or estimate the extent 
of fetal exposure to substances in the maternal circulation. However, one of the 
disadvantages of trying to determine the degree to which a particular transporter or 
enzyme influences any process, is the lack of availability of specific substrates. P-gp, 
MRP1/2, and BCRP, all of which are expressed on the apical trophoblast membrane, 
recognize a broad range of substrates, and there can also be overlapping substrate 
 149 
specificity. This could be a reason why in the presence of even a BCRP-specific 
inhibitor such as fumitremorgin C (FTC), only modest increases were observed in the 
accumulation of BODIPY® FL prazosin or mitoxantrone, both of which are BCRP 
substrates but are substrates of other transporters as well. A more conclusive 
approach towards determining the role of a particular transporter may be achieved in 
cells over-expressing these transporters. However, determining whether a particular 
transporter is involved in metabolite elimination or not, is further complicated due to 
the inhibitors affecting metabolism as well (i.e., as we have shown with the formation 
of 4-nitrophenylsulfate). Further, cells over-expressing a particular transporter would 
not help reach a conclusion on the relative contributions of the transporters in sulfate 
efflux in a particular tissue. One approach maybe to isolate the brush border and 
basolateral membranes, and then perform the study with sulfated standards in the 
presence of specific inhibitors of the efflux transporters. 
 
Figure 5.1 depicts all the transporters that may potentially eliminate sulfate 
metabolites out of syncytiotrophoblasts. In addition to the efflux transporters 
examined in chapter 4 for sulfate metabolite elimination, mRNA of several organic 
anion transporters (OATs) as well as organic anion transporting polypeptides 
(OATPs) are expressed in trophoblast [7, 8]. Protein expression or localization studies 
have been performed with only a few of these. The organic anion transporter 4 
(OAT4) and the organic anion transporting polypeptide 2B1 (OATP2B1) have been 
localized to the syncytiotrophoblast basolateral membrane, while OATP-E  
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Figure 5.1 General scheme of sulfate metabolite formation and elimination from 
the syncytiotrophoblast layer. The figure illustrates the transporters on the 
maternal-facing brush border and fetal-facing basal syncytiotrophoblast membranes, 
which have been found to, or could potentially play a role in sulfate metabolite 
elimination.  
 
(OATP4A1) is expressed on the apical syncytiotrophoblast membrane as shown in 
Figure 5.1 [2, 9]. The physiological function of placental OAT4 has been postulated 
to be the uptake of sulfated C19 steroids for de novo estrogen synthesis in the 
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placenta while both OAT4 and OATP-2B1 mediate the uptake of sulfoconjugated 
estrogens from the fetal circulation [2]. It has been suggested that placental OATP-E 
may mediate the uptake of thyroid hormones from the maternal circulation for 
transfer to the fetus [10]. OAT isoforms in the kidney eliminate several anionic drugs 
and in the intestine they have also been shown to expel sulfate metabolites [11, 12]. 
Whether the placental OAT and OATP isoforms contribute to the elimination of 
sulfate conjugates has not been examined so far, but this seems more than likely since 
none of the efflux inhibitors used in our study completely inhibited the efflux of 
either acetaminophen sulfate or 4-nitrophenylsulfate. Further, MRP3 and MRP4 are 
expressed on apical syncytiotrophoblast membrane. Both transporters eliminate 
sulfate metabolites across the hepatic sinusoidal membrane but similar roles in 
placenta have not been looked into.    
 
In early pregnancy, the trophoblast layer consists predominantly of cytotrophoblasts. 
With advancing gestation, the cytotrophoblast cells fuse together to form the 
multinucleated syncytiotrophoblast cells. There are functional differences between 
the cytotrophoblast cells and the syncytiotrophoblast. For example, BCRP and MRP2 
protein expression increased upon differentiation of cytotrophoblasts into 
syncytiotrophoblasts [13, 14]. The BeWo cell line, which primarily consists of 
cytotrophoblast-like cells, can be induced in vitro to syncytialize into multinucleated 
syncytiotrophoblast-like cells. The latter would be more reflective of the trophoblast 
layer of late pregnancy. It may be worthwhile to examine sulfotransferase and efflux 
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transporter function as the cytotrophoblasts differentiate into syncytiotrophoblasts. 
Any positive correlation would indicate a combined role of sulfotransferase enzymes 
and the efflux transporters in fetal protection. 
 
Finally, maternal disease states such as diabetes and intra-hepatic cholestasis of 
pregnancy (ICP) affect placental metabolism [15]. High altitude pregnancies and 
other maternal conditions such as hypertension, anemia, pulmonary disease, and 
preeclampsia can lead to fetal hypoxia which causes intrauterine growth restriction 
(IUGR) and low birth weight. Under hypoxic conditions several placental uptake or 
transport systems are modified [16]. Under such circumstances, it may be worthwhile 
to examine if hypoxia alters sulfotransferase enzyme expression in the placenta, as in 
rats hypoxia decreased acetaminophen sulfation [17]. 
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Abstract 
Purpose.  To investigate whether changes in extracellular pH affect the active efflux 
of colchicine, a non-ionizable P-glycoprotein substrate. 
Methods.  The effect of pH on P-glycoprotein (Pgp) functionality was studied by 
testing colchicine in bidirectional Caco-2 and mdr1-MDCK cell permeability assays 
in which the pH of the apical and basolateral chambers was varied.  In addition, drug 
uptake experiments were conducted under various pH buffer conditions. 
Results.  The apparent permeability of colchicine in the apical to basolateral direction 
(Papp,A to B) remained unchanged over the investigated pH range except at pH 4.5 
where it significantly differed.  More distinct changes were observed in the 
basolateral to apical permeability resulting in the permeability directional ratio (PDR) 
values being approximately 34 and 9 fold lower at pH values 4.5 and 5.0 compared to 
that at pH 7.4.  The permeability of digoxin was examined at pH values 4.5, 5.0 and 
7.4. There is a significant difference in Papp, A to B between pH values 4.5 and 7.4.  The 
PDR change is in the same order as that measured for colchicine; 47 compared to 34 
fold.  The uptake profile of colchicine changed dramatically due to the varying buffer 
pH. There was no increase in drug accumulation with time at pH values 7.4, 6.0 and 
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5.5. However, with buffers at pH 4.5 and 5.0 there was an increase in colchicine 
uptake with time similar to that observed for colchicine with a Pgp inhibitor. For the 
buffer conditions at pH values 4.5 and 5.0, an approximate 8 and 7 fold increase 
respectively in colchicine accumulation over 1 hour was observed compared to the 
accumulation at pH 7.4. 
Conclusion.  P-glycoprotein function, as assessed by the bidirectional transport of 
colchicine, is reduced as a result of changes in the extracellular pH. The efflux ratios 
of digoxin and colchicine were affected by pH to a different extent. The reduction of 
extracellular pH at or below 5.0 can inactivate Pgp function resulting in higher 
amount of drug accumulation inside the cells. 
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A.1 Introduction 
Drug transporters play a major role in drug distribution, disposition, as well as 
chemotherapy resistance.
1-3
  One subset of transporters, in particular, has recently 
been noted as clinically important; the family of ATP-binding cassette (ABC) efflux 
transporters.
4
 An important member of this family, P-glycoprotein (Pgp, MDR1 or 
ABCB1), was the first mammalian MDR linked transport protein to be discovered
5
 
and has been studied extensively for over 25 years.
6-9
 Despite the many years of study 
dedicated to the mechanism of action of Pgp, a single model describing how 
substances are transported does not yet exist.
7,9 
 The absence of a definitive model has 
negative implications for the development of effective anti-cancer drugs as the 
induction of Pgp in tumor cells leads to multi drug resistance which is a major cause 
of cancer treatment failure.  Pgp can also be found in normal human tissues.  It is 
present in the intestine, kidney, liver and brain vascular endothelium and therefore 
can participate in drug absorption and brain distribution.   
 
It has been shown that Pgp can reduce the oral bioavailability of a drug by reducing 
its intestinal absorption and by potentially enhancing its first pass metabolism.
10
 The 
pH of the gastrointestinal lumen is one among the many factors that affect the 
absorption of an orally administered drug. It varies along the different segments of the 
intestine, going from pH 4.5 beyond the pyloric sphincter which separates the 
stomach from the duodenum, ranging from 5.0 to 7.5 in the small intestine, and 
dropping to around 5.0 in the colon.
11,12
 Thus acidic and basic drugs are ionized to 
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different extents along the intestine. The passive absorption of charged drug 
molecules would be expected to vary as a function of intestinal pH because the 
lipophilic environment of the intestinal wall favors the permeation of the uncharged 
species as opposed to the ionized fraction.
13 
 The pH of the tumor microenvironment 
plays a similar role in the disposition of an anti-cancer drug.  The extracellular pH of 
tumor tissue is significantly lower than the extracellular pH of normal tissue.
14
  Many 
chemotherapeutic agents are weakly basic and become charged in the tumor 
microenvironment preventing their intracellular uptake and hence their efficacy.  
 
It is easy to understand how pH can affect the passive diffusion of a drug into a cell 
(pH-partition hypothesis)
13
 but how is Pgp efflux affected by pH conditions? 
Although there are several published papers in which the effect of pH on the function 
of the P-glycoprotein efflux transporter has been probed, the available data is 
somewhat conflicting as some studies have concluded that pH does not affect Pgp 
functionality while others have deduced that the function is altered by pH.
15-19  
One 
potential reason for this conflicting data was the use of test substrates and inhibitors 
that do not remain unionized in the pH ranges studied and therefore the effect of 
ionization on the passive permeability may have confounded the results.  In addition 
some compounds chosen in these studies were substrates for other drug transporters 
(e.g. daunorubicin which is also a BCRP substrate
20
).  
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The objective of the present study was to elucidate the effects, if any, of variable 
apical pH (4.5-8.0) on Pgp activity using Caco-2 cells as a model.  In order to isolate 
and systematically study the effect of pH on Pgp functionality, colchicine was chosen 
as a neutral Pgp test substrate. The change in extracellular pH, theoretically, should 
not alter the passive diffusion of colchicine. To specifically test if the observed effects 
are Pgp-mediated or not, the results obtained in Caco-2 cells were compared with 
those obtained in mdr1-MDCK cells. If pH-dependent changes in passive 
permeability and membrane properties can be ruled out, observed differences in the 
efflux ratio of colchicine can be contributed to Pgp function being affected by 
changes in the extracellular pH. 
 
A.2 Materials and methods 
A.2.1 Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM) buffered with HEPES was obtained 
from Gibco Invitrogen (Carlsbad, CA). All other cell culture reagents were from 
Mediatech (Herndon, VA). Transwell plates were obtained from Costar Corporation 
(Acton, MA). Digoxin and colchicine were purchased from Acros Organics. 
Alprenolol was purchased from MP Biomedicals, INC. (Solon, OH). Zosuquidar 
trihydrochloride (LY3359793) was purchased from API Services INC. (Westford, 
MA), Lucifer yellow, testosterone, sodium acetate trihydrate, 2-(N-morpholino) 
ethanesulfonic acid (MES) and HEPES were obtained from Sigma-Aldrich (St. Louis, 
MO).  Caco-2 cells originating from a human colorectal carcinoma were acquired 
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from American Tissue Culture Collection (Manassas, VA). The MDCK cells 
transfected with the human mdr1 gene (mdr1-MDCK)
21,22
 were from Dr. Piet Borst 
(The Netherlands Cancer Institute, Amsterdam, The Netherlands). 
 
A.2.2 Cell culture 
Caco-2 cells and mdr1-MDCK cells were grown at 37
o
C in an atmosphere of 5% CO2 
and 90% relative humidity. Caco-2 cells were maintained in Dulbecco’s modified 
Eagles medium (DMEM) supplemented with 10% heat-inactivated fetal bovine 
serum, 100 I.U./ml penicillin and 100 µg/mL streptomycin, and 10 mM nonessential 
amino acids. The mdr1-MDCK cells were maintained using the same culture 
conditions with the exception of the media being supplemented with 20 nM 
colchicine to preserve selective pressure.
23 
Confluent cell monolayers were 
subcultured every 7 days by treatment with 0.25% trypsin containing 1 mM EDTA.  
 
A.2.3 Bidirectional transport studies 
Caco-2 cells were seeded at a density of 80,000 cells/cm
2
 in 12 well plates on 
polycarbonate filters (Costar Transwell
®
 cell culture inserts, 12.0 mm diameter, 3.0 
micron pore size). Caco-2 cells were grown on filters for 21-25 days. The mdr1-
MDCK cells were seeded at a density of 50,000 cells/cm
2 
in 12 well plates on 
polycarbonate filters (Costar Transwell
®
 cell culture inserts, 12.0 mm diameter, 0.4 
micron pore size).  The mdr1-MDCK cells were grown for 6-8 days.  Caco-2 cells of 
passage numbers 41 to 60 and mdr1-MDCK cells of passage numbers 6 to 14 were 
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used for all experiments in this paper.  Prior to the transport studies, the culture 
medium was replaced with HBSS at pH 7.4 and equilibrated for 30 minutes at 37
o
C. 
For transport studies that involved a pH gradient across the monolayer, the apical 
chambers contained a drug/buffer solution at pH values varying from 4.5-8.0 while 
the basolateral chamber contained drug/buffer solution at pH 7.4.  HBSS was 
buffered with 10 mM sodium acetate for pH 4.5, 5.0; 10 mM MES for pH 5.5, 6.0; 
and 25 mM HEPES for pH 8.0. For pH 7.4, initially HBSS was used which was later 
changed to HBSS buffered with 25 mM HEPES (an explanation for the change is 
provided in the Results and Discussion section). For the other studies, both chambers 
contained drug/buffer solutions at the same pH. Drug solutions were prepared in 
HBSS (at the adjusted pH value for the experiment) at a concentration of 20 µM for 
digoxin, colchicine, and testosterone and added to either the apical (AP) or basolateral 
(BL) sides of the cell monolayers.  The volume of solution added to the apical 
chamber was 0.5 mL while that added to the basolateral chamber was 1.0 mL. The 
transport experiments were carried out in an oven maintained at 37
o
C. The plates 
were shaken at 100 rpm using an orbital shaker (Lab-Line Instruments, Melrose Park, 
IL) for the duration of the experiment (1 hour).  At discrete time intervals, 200 µL of 
the receiver chamber solution was withdrawn and replaced with fresh buffer solution 
(sink condition).  The integrity of the cell monolayer was assessed by measuring the 
permeability of the paracellular marker Lucifer yellow (100 µM). If the apparent 
permeability coefficient of Lucifer yellow was found to be less than 0.3 x 10
-6
 cm/sec, 
the cell monolayers were considered acceptable to use in experiments. Colchicine, 
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digoxin, and testosterone samples were analyzed by LCMS (an integrated Cohesive 
Technologies LX-2 series liquid chromatography system coupled with an Applied 
Biosystems MDS-SCIEX 4000 Q Trap triple quadrupole mass spectrometer (Foster 
City, CA)). The Lucifer yellow samples were measured using a Wallac 1420 
Multilabel Reader; using a 485 nm excitation and 535 nm emission (Perkin Elmer 
Life Sciences, Waltham, MA). 
 
A.2.4 Permeability calculations 
The following equation was used to calculate apparent permeability
24 
in either the 
apical to basolateral direction (Papp,A to B) or basolateral to apical direction (Papp,B to A) : 
Papp = dC/dt x Vr/A x Cd 
Where dC/dt is the change in concentration in the receiver compartment with respect 
to time, Vr is the volume of the receiver compartment, A is the growth surface area, 
and Cd is the initial concentration of the drug in the donor compartment. Mass balance 
was calculated for each experiment.  In all transport experiments the mass balance 
was greater than 70%.  
A permeability directional ratio (PDR) was calculated as follows: 
PDR = Papp, B to A/ Papp, A to B 
 
A.2.5 Drug uptake studies 
All drug uptake experiments were performed using mdr1-MDCK cells seeded in 6 
well tissue culture plates at a density of 60,000 cells/mL and grown for 5 days. Prior 
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to the uptake studies, the cells were washed twice with pre-warmed (37°C) HBSS 
buffer solution. The buffer solutions at various pH values were prepared as previously 
mentioned.  The cell monolayers were then incubated with 4 mL of test compound 
solution (1 µM) at 37°C on an orbital shaker (rotation speed 100 rpm) for up to one 
hour.  At discrete time intervals, the drug solution was removed from the wells and 
cells were washed twice with ice-cold HBSS and lysed in 1 mL of freshly prepared 
lysis buffer which consisted of 20 mM ammonium acetate/methanol (4:1) and 
alprenolol (20 ng/mL) as an internal LCMS standard. Contents of each well were 
centrifuged at 14,000 rpm for 15 minutes and 200 µL of the supernatant was then 
transferred for quantitation by LCMS. The concentration of the test drug was then 
measured using a standard curve prepared by spiking known concentrations of the 
drug into the lysis buffer.  The percent uptake was calculated by dividing the amount 
of drug recovered from the lysed cells by the amount of drug applied to the cells.  For 
the uptake studies with a Pgp inhibitor, the cells were preincubated with a 1 µM 
solution of zosuquidar
25
 for 30 minutes. The cells were then washed with fresh HBSS 
and the drug/inhibitor solution (1 µM for both) was applied and the experiment was 
completed as outlined above. Protein content of the mdr1-MDCK cells grown in 
individual wells of the 6-well plates was determined separately by Quant-iT™ Protein 
Assay Kit with a Qubit™ fluorometer (Invitrogen™, Carlsbad, CA). The extraction 
solution containing ammonium acetate and methanol was not used in order to prevent 
damage to the extracted proteins. Instead, lysis buffer containing TX-100 was used as 
reported in the literature.
26
 Cells were dissolved in 1 mL of freshly prepared lysis 
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buffer consisting of 1% TX-100 (v/v), 20 mM Tris HCl and 150 mM NaCl. The 
average protein content per well for the mdr1-MDCK cells (n = 6) was found to be 
2.55 ± 0.06 mg/mL and 2.57 ± 0.14 mg/mL for two different cell passages. Based on 
this data it was concluded that normalization of the uptake data for protein content 
was not necessary and all drug percent uptake values were reported based on LCMS 
data (as described above).   
 
A.2.6 Statistical analysis 
All experiments were performed at a minimum in triplicate. Statistical significance 
was calculated with one-way Analysis of Variance (ANOVA) followed by Tukey’s 
post comparison test, or the Student’s t-test as appropriate. A p-value of less than 0.05 
was considered to be statistically significant. The fold differences mentioned in the 
paper were derived by dividing the permeability directional ratios. 
 
A.3 Results  
A.3.1 Caco-2 cell monolayer integrity 
To establish the integrity of the Caco-2 cell monolayers in the pH range of the 
transport studies (4.5 to 8.0), the permeability of the paracellular permeability marker 
Lucifer yellow (LY) in several buffers at different pH values was investigated (Table 
I). In agreement with earlier published reports the cell monolayer did not become 
leaky upon exposure to various pH conditions.
24,27
 Note that the Caco-2 monolayer 
integrity for each set of passaged cells was routinely tested at pH 7.4. Monolayers 
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with Papp values greater than 0.3 x 10
-6
 cm/sec were considered to be unsuitable for 
the transport studies. 
 
In another experiment designed to monitor potential changes in the condition of the 
Caco-2 cell monolayer in the pH range of the planned transport studies, the 
bidirectional permeability of testosterone was measured at pH values 4.5 and 7.4 
(Table II).  Testosterone is a neutral compound known to be a substrate of CYP3A4 
but not a substrate of Pgp.
28,29
  No difference in the permeability directional ratio 
(PDR) value of testosterone was observed by changing the pH from 7.4 to 4.5 (Table 
II) providing additional evidence the Caco-2 cell monolayer is remaining intact 
during the transport experiment.    
 
 
Table I.  Permeability of Lucifer yellow across Caco-2 monolayers as a function of 
pH (n = 3).  AP and BL represent apical and basolateral chambers. 
 
 
Compound pH (AP/BL) Papp,A to B x 10
6 
(cm/s) 
LY (100 µM) 4.5 /7.4 0.09 ± 0.01 
LY (100 µM) 5.0/7.4 0.12 ± 0.06 
LY (100 µM) 7.4/7.4 0.07 ± 0.01 
LY (100 µM) 8.0/7.4 0.15 ± 0.03 
LY (100 µM) 4.5/4.5 0.08 ± 0.01 
LY (100 µM) and  
20 µM colchicine 
4.5/7.4 0.18 ± 0.04 
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Table II.  Permeability of testosterone across Caco-2 monolayers as a function of pH 
(n = 3).  AP and BL represent apical and basolateral chambers.  The number in 
brackets shows the fold change compared with the value at pH 7.4. 
 
pH 
(AP/BL) 
Papp, A to B x 10
6
 
(cm/s) 
Papp, B  to A  x 10
6 
(cm/s) PDR 
4.5/4.5 24.0 ± 0.9 (2x) 20.4 ± 0.8 (2x) 0.9 + 0.1 
7.4/7.4 11.0 ± 1.9 10.1 ± 2.8 0.9 + 0.3 
 
 
A.3.2 pH-dependent bidirectional transport of colchicine and digoxin across 
Caco-2 cell monolayers  
Since, colchicine has a pKa of 12.35,
30
 within the pH range 4.5-8.0 the concentration 
of the unionized species is not expected to change. Hence, the passive permeability of 
colchicine should not be affected by pH.  It has been demonstrated previously that the 
polarized transport of colchicine across Caco-2 cell monolayers is mediated by P-
glycoprotein.
31
 Generally, compounds exhibiting asymmetrical transport and 
exhibiting permeability directional ratio (PDR) values of 2 or greater are considered 
to be substrates of efflux transporters.
24
  Observed variances in the PDR values due to 
pH change would indicate that P-glycoprotein functionality is being affected by pH, 
thus the permeability of colchicine was examined in the presence of a pH gradient. 
The apical side pH values were varied between 4.5 and 8.0 while the basolateral side 
pH was kept at 7.4 (Figure I). 
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Figure I.   Apparent permeability of 20 µM colchicine across Caco-2 cell monolayers as a 
                 function of apical pH (basolateral pH 7.4). Each bar represents mean ± SD, (n=3).
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Apical 
pH 
Papp, A to B x 10
6
 
(cm/s) 
Papp, B  to A  x 10
6 
(cm/s) PDR 
4.5 0.57 ± 0.08  0.66 ± 0.09 1.2 + 0.2 (23x) 
5 0.24 ± 0.03  2.53 ± 0.11 10.5 + 1.2 (3x) 
5.5 0.14 ± 0.02  4.31 ± 0.36 30.8 + 5.3  
6 0.15 ± 0.03 5.78 ± 0.37 39.7 + 7.8  
7.4 0.17 ± 0.01 4.69 ± 0.10 27.4 + 1.7  
8 0.12 ± 0.02 4.52 ± 0.18 37.4 + 6.1  
           The number in brackets shows a significant fold change compared with the 
value at pH 7.4.    
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As can be seen in Figure I, the Papp,A to B remained unchanged over the investigated pH 
range except at pH 4.5 where it significantly differed.  More distinct differences were 
observed in the basolateral to apical permeability resulting in the PDR values being 
23 and 3 fold lower at apical pH values of 4.5 and 5.0 from that at 7.4.  It has been 
shown that Pgp mediated efflux is asymmetric with respect to absorptive and 
secretory transport,
29
 thus the larger change in basolateral to apical permeability with 
respect to the change in apical to basolateral permeability is not surprising.  
 
The permeability of Lucifer yellow was tested in the presence of 20 µM colchicine at 
an apical pH of 4.5 (the lowest pH value used in the study) to see if the altered PDR 
was a result of the colchicine affecting the monolayer integrity at lower pH values. As  
 
Table III.  pH values at the start and end of the bidirectional Caco-2 permeability 
studies.   
pH (A/B) 
t = 0 
Apical pH 
t = 120 min. 
 
          HBSS                   HEPES 
Basolateral pH 
t = 120 min. 
 
          HBSS                    
HEPES 
4.5/7.4 5.5 6.0 7.2 7.4 
5.0/7.4 5.9 6.1 7.0 7.3 
5.5/7.4 5.7 5.7 6.9 7.5 
6.0/7.4 6.1 6.1 7.5 7.4 
8.0/7.4 8.0 8.1 7.4 7.5 
 
can be seen in Table I, the monolayer was not compromised. However, pH 
measurement at the end of the experiments indicated that the apical and basolateral 
chambers were equilibrating (Table III).  Changing to a 25 mM HEPES buffered 
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HBSS solution instead of HBSS alone for maintaining a pH of 7.4 as has been 
previously reported
15
 did not stabilize the initial pH values.    
 
The colchicine permeability experiments were repeated with the same pH on the 
apical and basolateral sides.  In the absence of a pH gradient, the results were 
qualitatively similar to those obtained with a pH gradient (Figure II).  The PDR was 
34 fold and 9 fold lower at pH 4.5 and 5.0 compared to the PDR value measured at 
pH 7.4. The low PDR values obtained at pH 4.5 and 5.0, indicate the possibility of 
Pgp mediated transport being impaired at the low pH values. 
 
It has been shown previously by Neuhoff et al. that the efflux ratio of digoxin across 
Caco-2 cell monolayers is independent of apical pH (pH range tested: 5.0 to 8.0).
15
 
To test if the permeability and PDR differences are specific to colchicine, the 
permeability of digoxin was examined at pH values 4.5, 5.0 and 7.4. There is a 
significant difference in Papp, A-B between the pH values 4.5 and 7.4 (Table IV).  The 
PDR change is on the same order as measured for colchicine; 47 compared to 34 fold. 
Compared to the average efflux ratio for digoxin over the pH range 5.0 to 8.0 
reported by Neuhoff (8.9 + 0.8)
15
 this finding is quite different. There is a possibility 
that the inconsistencies are due to the different experimental methodologies, such as a 
higher stirring rate (450 rpm) and removal of the entire contents of the receiver 
chamber at experimental time points in the Neuhoff study.  
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Figure II.   Apparent permeability of 20 µM colchicine across Caco-2 cell monolayers as a function of 
                 pH (apical and basolateral pH values the same). Each bar represents mean ± SD, (n=3).
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pH 
Papp, A to B  x 10
6
 
(cm/s) 
Papp, B to A  x 10
6
 
(cm/s) PDR 
4.5 1.54 ± 0.27 1.24 ± 0.04 0.8 + 0.1 (34x) 
5.0 0.50 ± 0.11 1.49 ± 0.18 3.0 + 0.8 (9x) 
5.5 0.11 ± 0.01 2.76 ± 0.13 26.2 + 2.7  
6.0 0.27 ± 0.06 3.31 ± 0.04 12.5 + 2.9 (2x) 
7.4 0.17 ± 0.01 4.69 ± 0.10 27.4 + 1.7 
8.0 0.24 ± 0.10 3.63 ± 0.20 15.2 + 6.1 (2x) 
The number in brackets shows a significant fold change compared with the 
value at pH 7.4. 
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Table IV.  Comparison of the bidirectional transport of 20 µM colchicine and 
digoxin across Caco-2 cell monolayers (same apical and basolateral pH values). The 
number in brackets shows a significant fold change compared with the value at pH 
7.4. 
 
pH Colchicine Digoxin 
 Papp, A to B 
 x 10
6
 
(cm/s) 
Papp, B to A  
 x 10
6
 
(cm/s) 
PDR Papp, A to B 
x 10
6
 
(cm/s) 
Papp, B to A 
x 10
6
 (cm/s) 
PDR 
 
4.5 
 
1.54 ± 0.27 
 
1.24 ± 0.04 
0.8 + 0.1 
(34x) 
 
23.5 ± 0.1 
 
24.0 ± 0.3 
1.0 + 1.1 
(47x) 
 
5.0 
  
0.50 ± 0.11 
 
1.49 ± 0.18 
3.0 + 0.8 
(9x) 
 
0.75 + 0.07 
 
11.3  ± 0.8 
15.2 + 1.8 
(3x) 
 
7.4 
0.17 ± 0.01 4.69 ± 0.10 27.4 + 
1.7 
 
2.43 ± 0.13 
 
114.0 ± 10.3 
 
47.0 + 4.9 
 
 
A.3.3 pH-dependent bidirectional transport of colchicine across mdr1-MDCK 
cell monolayers   
As confirmation that the pH-dependent efflux of colchicine observed in Caco-2 cells 
is indeed due to Pgp, transport studies in the presence of a pH gradient were 
conducted using Madine Darby Canine Kidney (MDCK) cells transfected with the 
human mdr1 gene.
21,22
 As observed with the Caco-2 cell transport experiments, the 
PDR changes significantly upon lowering the apical side pH from 7.4 to 4.5 (Figure 
III) in the mdr1-MDCK cell experiments.  This data provides further verification  that 
P-glycoprotein functionality is affected by pH.   
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Figure III.   Apparent permeability of 20 µM colchicine across mdr1-MDCK cell monolayers as a 
                   function of pH. Each bar represents mean ± SD, (n=3).
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pH 
Papp A to B  x 10
6
 
(cm/s) 
Papp B to A  x 10
6
 
(cm/s) PDR 
4.5 1.93 ± 0.38 1.24 ± 0.04 1.8 + 0.4 (9x) 
7.4 0.29 ± 0.06 4.55 ± 0.41 15.5 + 3.5 
The number in brackets shows a significant fold change compared with the 
value at pH 7.4. 
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A.3.4 pH-dependent uptake of testosterone and colchicine in mdr1-MDCK cells 
The uptake of colchicine in mdr1-MDCK cells was studied as a function of the buffer 
pH value to further investigate the effect of pH on Pgp functionality. The level of 
colchicine uptake in mdr1-MDCK cells was found to be constant at pH 7.4 for one 
hour. However, treatment of the mdr1-MDCK cells with the Pgp inhibitor 
zosuquidar
25 
allowed the colchicine cell concentration to increase with time (Figure 
IV) demonstrating that reduced Pgp activity caused increased drug accumulation.  
Comparison of the uptake profile for colchicine with and without Pgp-inhibitor shows 
more than a 6 fold increase in drug uptake in the presence of the inhibitor (Figure IV).  
Before investigating the effect of pH on colchicine uptake, testosterone was again 
used as a test control to monitor potential changes in the cell membrane integrity.  
The transport assay for testosterone showed no pH effect on the permeability 
directional ratio. Performing an uptake assay with testosterone at pH values 4.5 and 
7.4 showed no difference in testosterone uptake with time (Figure V). Instead, a 
decrease in testosterone recovered from the cell can be observed over time, the 
decrease being more pronounced at pH 7.4.  This is possibly due to the metabolism of 
testosterone to 6β-OH testosterone by CYP3A4.
32,33
  It is reasonable to postulate that 
CYP3A4 is being effected by pH as well and the metabolism of testosterone was 
more extensive at pH 7.4 compared to at pH 4.5. 
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Figure IV.  Colchicine (1µM) uptake by mdr1-MDCK cells with and without a Pgp inhibitor
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Figure V. Testosterone (1µM) uptake by mdr1-MDCK cells at pH 7.4 and 4.5 
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In order to monitor the effect of pH on the colchicine uptake profile, mdr1-MDCK 
cells were incubated with colchicine in different pH buffers for one hour. Figure VI 
shows a remarkable change of the uptake profile for the drug due to the varying  
 
Figure VI.  Colchicine (1 µM) uptake by mdr1-MDCK cells as a function of pH value
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buffer pH. There was no increase in drug accumulation with time at pH values 7.4, 
6.0 and 5.5. However, with buffers at pH 4.5 and 5.0 there was an increase in 
colchicine uptake with time similar to that observed for colchicine with the Pgp 
inhibitor. For the buffer conditions at pH values 4.5 and 5.0, an approximate 8 and 7 
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fold increase in colchicine accumulation over 1 hour was observed compared to the 
accumulation at pH 7.4 (Figure VI). 
 
A.4 Discussion  
Initially, to simulate in vivo conditions, the permeability of 20 µM colchicine was 
examined in the presence of a pH gradient in Caco-2 cells.
34
 Except at pH 4.5, 
colchicine exhibited apically-directed asymmetrical bidirectional transport (Figure I). 
The PDR was between 31-37 in the pH interval 5.5-8.0 with no increasing or 
decreasing trends and the value at pH 7.4 was in agreement with the efflux ratio of 
colchicine that has been previously reported (PDR = 27.4).
29
 In contrast, at pH 5.0 the 
PDR was approximately 3 fold lower than at pH 5.5, resulting from an almost 60% 
decrease in Papp, B to A and a 1.7 fold increase in Papp, A to B.  At pH 4.5, the asymmetry 
in transport was abolished as witnessed by a PDR of 1.2. Compared with the apparent 
permeability rates at pH 5.0, this resulted from an approximately 25% decrease in the 
Papp, B to A, and a 2.4 fold increase in the Papp, A  to B. The PDR at pH values 4.5 and 5.0 
were 23 and 3 fold lower than that at pH 7.4 respectively.        
 
The change in the efflux ratio indicates that pH could be affecting Pgp function. It has 
been demonstrated before that in a pH gradient system, a different extent of ionization 
in the apical and basolateral chambers can generate a passive efflux ratio leading to 
an over estimation of the contribution of efflux transporters.
15
 Colchicine is a neutral 
molecule, therefore pH-dependent changes in passive permeability would not be 
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expected in the investigated pH range and no contribution from a passive efflux ratio 
would not be generated. Another possibility could be that the altered apparent 
permeability and efflux ratio are resulting from pH-mediated changes in the 
properties of cellular membranes. The monolayer integrity was verified by 
performing permeability experiments with the paracellular permeability marker 
Lucifer yellow (Table I). If Pgp function was selectively influenced by the change of 
pH, the permeability of a neutral non Pgp substrate should not have been affected 
under this conditions. Testosterone is a substrate for CYP3A4 but not for Pgp.
28,32
 
Results from the testosterone transport experiments show that for testosterone there 
was a slight difference in permeability rate coefficients with the Papp at pH 7.4 two 
fold less than the Papp at pH 4.5 (Table II). Unlike colchicine, there is no change in the 
permeability directional ratio. Furthermore, the testosterone apparent permeability 
rate coefficient (A to B) measured at pH 7.4 is in agreement with the published value 
(Papp, A to B = 24.9 + 3.3 x 10
-6
 cm/s).
35 
   
 
This first set of transport experiments was conducted using a pH gradient (apical pH 
varied, basolateral pH kept at pH 7.4).  The pH of the chambers changed during the 
course of the experiment (Table III) so in order to directly study the effects of pH on 
Pgp functionality the experiments were repeated in the absence of a pH gradient 
(same apical and basolateral pH). There were changes in absolute values but no 
increasing or decreasing trends in the PDR in the extracellular pH range of 5.5-8.0.  
In accordance with the previous studies there was an increase in efflux ratio going 
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from pH 4.5 to pH 5.5 (Figure II). At pH 4.5, the PDR was ~3.5 fold lower than that 
at pH 5.0, while at pH 5.0 it was ~8.5 fold lower than that at pH 5.5. Thus, in studies 
conducted both in the absence as well as the presence of a pH gradient, a decrease in 
extracellular pH was accompanied by a decrease in Papp, B to A, an increase in Papp, A to B, 
and a decrease in PDR.  These results confirm the possibility of reduced function of 
the transporter at acidic pH conditions.  
 
The apically directed asymmetrical transport of colchicine indicates that it is being 
transported by an efflux transporter located on the apical membrane of Caco-2 cells. 
In addition to Pgp, several other efflux transporters are expressed in Caco-2 cells 
including the breast cancer resistance protein (BCRP) and the multidrug resistance 
associated proteins MRP2 and MRP3.
36,37
  Both BCRP and MRP2 are located on the 
apical membrane of Caco-2 cells,
38,39
 but colchicine has been found to be a substrate 
of Pgp only.
20
 To further confirm that the altered efflux ratio is due to modified Pgp 
function, the permeability of 20 µM colchicine was measured in mdr1-MDCK cells in 
the absence of a pH gradient. MDCK cells that have been transfected with the human 
mdr1 gene are frequently used to screen for Pgp substrates as they lack any 
significant levels of other transporters.
40
  As seen with Caco-2 cells, the asymmetric 
transport of colchicine observed at pH 7.4 was attenuated at pH 4.5 (Figure III). 
According to the conclusions drawn from the Caco-2 permeability data, if P-
glycoprotein is dysfunctional at acidic pH, then with decreasing pH the Papp, A to B 
should increase while the Papp, B to A should decrease. In agreement with this 
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hypothesis, Papp, A to B increases with decreasing pH but contrary to it, the Papp, B to A 
also increased with decreasing pH (Figure III). It has been noted that the different 
apical membrane compositions of MDCK and Caco-2 cells could result in different 
orientations of Pgp in the membranes and this could be a possible reason for the 
different affinities of Pgp substrates/inhibitors observed in the two cell types.
40 
Both 
the reduction of asymmetric transport as well as the increased apical to basolateral 
permeability observed at pH 4.5, indicate that Pgp mediated transport of colchicine is 
being reduced under acidic pH conditions.    
 
The observation that Pgp functionality is reduced at low pH values is contrary to 
other reports in the literature. Altenberg et al. performed efflux studies with the Pgp 
substrate rhodamine 123 in various drug resistant cell lines and showed that changes 
in the intra- or extracellular pH environment did not mediate Pgp activity (pH range 
5.5-7.5).
20
  Thews et al. reported that the reduction of extracellular pH to 6.6 led to an 
increase of Pgp mediated efflux activity in rat prostrate cells when compared to 
control cells with an extracellular pH value of 7.4.
18 
They found that the Pgp activity 
was doubled after 3 to 6 hours of incubation in acidic medium (pH 6.6) without an 
increase in Pgp expression level. They also reported that the cytotoxicity of a Pgp-
substrate drug daunorubicin was reduced in the acidic environment. The reduced 
cytotoxicity was attributed to the higher activity of the efflux transporter under this 
condition. Since daunorubicin is a basic drug (pKa of 8.4),
41
 the lowered activity 
could be explained by the pH-partition hypothesis in which the lipid bilayer of the 
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cell wall favors the permeation of the uncharged species as opposed to the ionized 
fraction.
13
 The transport of basic drugs across cells is governed by the concentration 
of the uncharged species which in turn is determined by pH.
15,17,24 
 Thus the uptake of 
the weakly basic daunorubicin (and related cytotoxicity) is impaired at a low pH. In 
fact the acidic microenvironment of tumors is one of the confounding factors in 
developing an effective anti-tumor drug.
42-44
 
 
Since several of the preceding literature reports have utilized uptake experiments to 
investigate pH and Pgp functionality; a comparable experiment was conducted in 
which the accumulation of colchicine in mdr1-MDCK cells under various pH 
conditions was examined. Hafny et al. looked at the colchicine cellular kinetics in 
immortalized rat brain microvessel endothelial cells.
45 
Colchicine uptake was reported 
to show two phases with an initial rapid entry followed by constant rate of 
accumulation for 10 nM [
3
H] colchicine. Equilibrium colchicine concentration was 
achieved after 45 hours in the concentration range of 0.5 nM to 20 nM.  However, 
Hafny found that increasing the concentration of colchicine to 200 nM reduces the 
time required for attaining the maximum level of drug uptake to 6 hours.  In our 
studies we used 1 µM colchicine to ensure adequate sensitivity for LCMS detection 
technique. An initial increasing uptake phase for the drug leading to equilibrium level 
inside the cell at pH 7.4 was not observed. Instead the amount of colchicine recovered 
from the cell appeared constant after 5 minutes at pH values 7.4 (Figure IV). It is 
possible that under this condition the intracellular colchicine level has reached a 
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maximum in less than 5 minutes. Incubation of the mdr1-MDCK with a Pgp inhibitor 
(zosuquidar) for thirty minutes prior to the uptake experiment led to increasing 
colchicine accumulation with time (Figure IV). A similar effect is observed when the 
uptake experiment is performed with colchicine alone under pH conditions at pH 4.5 
and 5.0 (Figure VI) which indicates that at these low pH values Pgp function is 
diminished. 
 
To see if the same phenomenon could be observed with other Pgp substrates, the 
bidirectional permeability study with Caco-2 cells was repeated using digoxin 
(20µM), another neutral Pgp substrate.  The digoxin PDR decreased with decreasing 
pH although a dramatic change was not detected until the pH was lowered to 4.5 
(Table IV). Neuhoff et al. have previously demonstrated that the efflux ratio of 
digoxin (8.9 ± 0.8) across Caco-2 is independent of the apical pH in the range 5.0 to 
8.0. Based on this data, Neuhoff concluded that Pgp function is not impacted by pH 
which is contrary to our findings.  There a several notable differences in the 
experimental design of the two studies such as the length of time, orbital stirrer 
setting, and test sampling. It is difficult to attribute the differences in data to these 
variables without further evaluation.  
 
In conclusion, our data indicates for the first time that P-glycoprotein function, as 
assessed by the bidirectional transport of colchicine, is being reduced as a result of 
changes in the extracellular pH. The decrease in Papp, A to B and increase in Papp, B to A 
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with decreasing pH indicate that at least in the pH range 4.5-5.5 the function of the 
pump is being impaired with decreasing pH. It appears that the efflux ratios of 
digoxin and colchicine were affected by pH to a different extent.  
 
The uptake study clearly shows that reduction of extracellular pH at or below 5.0 can 
inactivate the Pgp function resulting in higher amount of drug accumulation inside the 
cells. In the future, it might be possible to develop formulations which can reduce the 
pH of the tumor microenvironment to pH values which leads to transient inactivation 
of P-glycoprotein efflux.  Additional studies of this nature are warranted as these data 
may provide important insight to the elucidation of the P-glycoprotein efflux 
mechanism and ultimately the development of a successful chemotherapy for multi 
drug resistant tumors. 
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